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Biolaser are an emerging technology for next generation biochemical detection and clinical 
applications. Laser-based detection offers the distinct advantages over fluorescence-based 
detection in terms of signal amplification, narrow linewidth, and strong intensity, leading to orders 
of magnitude increase in detection sensitivity. Recent advances have been made to achieve lasing 
from biomolecules and single cells. Tissues, which consist of cells embedded in extracellular 
matrix, mimic more closely the actual complex biological environment in living bodies, and thus 
are of more practical significance in medicine. The aim of this research is to develop optofluidic 
biolasers at the tissue level in order to provide a novel analytical tool for a wide range of biological 
and biomedical applications.  
During my research, several types of micro-laser cavities, such as optofluidic ring 
resonators and high-Q Fabry-Pérot resonators were implemented to achieve lasing in tissues. 
Distinct and controllable laser emissions from various tissues thus enable highly 
multiplexed/multifunctional detection with superior contrast and high spectral/spatial resolution. 
In terms of biological applications, we first demonstrated chlorophyll lasing with intrinsic gain 
medium extracted from leaves, suggesting the possibility to lase with natural biological tissues. In 
addition, we developed a versatile tissue laser platform in which biological tissues were doped 
with different dyes and sandwiched within a high-Q Fabry-Perot cavity. Detailed investigation on 
how tissue structure/geometry, tissue thickness, and staining dye concentration affect the tissue 
laser was conducted.  
xi 
 
To signify potential implementations of the tissue lasers in biomedicine, lasing in two 
major types of clinical tissues were investigated, including liquid biopsy and surgical biopsy.  
Herein, we demonstrated the first “blood laser” using the only FDA approved near infrared dye, 
Indocyaine Green, in human whole blood with the ICG concentration within the normal range of 
clinical dosage. Furthermore, we developed the first “laser emission-based microscope” (LEM) 
for improved cancer evaluation by mapping the lasing emissions from nuclear biomarkers in 
human lung and colon cancer tissues. As a proof-of-concept, tissue samples from  patients labelled 
with cancer biomarkers were tested while an excitation laser beam was scanned to build a laser-
emission image. It is found that nuclei in the cancer and normal tissues have vastly different lasing 
thresholds due to different expressions of nucleic acids and nuclear proteomic biomarkers, which 
enables the LEM to distinguish, with a high contrast, the cancer and normal tissues, and the cancer 
tissues with and without nuclear proteomic biomarkers. Significantly, the LEM has demonstrated 
a great potential to diagnose early stage cancer tissues with a high sensitivity of 97.5%. We also 
presented the wavelength-multiplexed immuno-lasing capability of LEM. As a final remark, we 
achieved lasing in living neurons/neuronal networks and employed laser emission to detect the 
subtle transients of intracellular calcium dynamics in neurons in vitro. Calcium imaging and 
recording of spontaneous neuronal activities were demonstrated with the “neuron lasing” method, 
in which the relative changes were significantly improved 1000 fold compared to fluorescence-
based measurement. This thesis marks a critical step towards eventual clinical and biomedical 
applications of optofluidic biolasers, which may find broad use in precision medicine with on-chip 
cancer screening and immunodiagnostics, as well as in brain-on-chip devices, neuro-analysis, 
tissue engineering, and fundamental cell biology.  
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Chapter 1                                                                                   
Introduction 
1.1.   Optofluidic biolasers 
Optofluidic biolasers are an emerging technology for next generation biochemical 
detection and clinical applications. In particular, optofluidic biolasers are a class of lasers in which 
the gain medium is composed of biologically related materials submerged in a liquid environment 
and integrated with a micro-laser cavity1-6. With the development of micro-fabrication technology, 
various types of bio-compatible cavities have been developed for biolasers such as ring resonator7, 
Fabry-Pérot cavity (FP)8,9, distributed feedback laser cavity10, microsphere resonator11, photonic 
crystal12, and random laser cavity13, as shown in Fig. 1.1. Additionally, there exist numerous types 
of gain media compatible with liquid and biological environments such as fluorescent compounds 
(luciferin14, vitamins15, and dyes16), natural fluorescent proteins17-19, and quantum dots20,21.  
In particular, one of the most prominent applications for the optofluidic biolaser is the 
highly sensitive bioanalysis5,6,22. Fig. 1.2 illustrates the major differences between the conventional 
fluorescence-based and the laser-based bioanalysis. In the conventional detection, the fluorescent 
sample is in a cuvette or on a glass slide. Fluorescence (i.e., spontaneous emission) is used as the 
sensing signal. A small change in the underlying biological process/interaction leads to a small 
change in fluorescence, which may be undetectable due to the omnipresent background noise. In 
contrast, in the optofluidic laser based detection, the fluorescent sample is placed inside a laser 
cavity and becomes part of the laser (as the laser gain medium). Rather than fluorescence, the laser 
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emission (i.e., stimulated emission) is used as the sensing signal. Thanks to the strong optical 
feedback provided by the cavity, a small change in the gain induced by the underlying biological  
 
Figure 1.1. Biolasers with different optical cavities. (a) Optofluidic ring resonator23. (b) Fabry-
Perot mirror cavity9. (c) Photonic crystal based biolaser integrated with microfluidics24. (d) 
Distributed feedback biolaser25. (e) Random laser without external cavity. (f) Microsphere/droplet 
based whispering gallery mode laser17. 
 
 
Figure 1.2. Comparison between conventional fluorescence-based and laser-based detection. 
(a) Fluorescence based method does not have threshold behavior and the spectrum is usually very 
broad. Laser based method provides a lasing threshold and narrow linewidth (<1 nm).6 
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processes/interaction are significantly amplified, leading to a drastic change in the laser output 
characteristics (e.g., intensity, lasing threshold, emission directionality, and spatial mode 
distribution). Through recent theoretical analysis and experimental work , optofluidic biolasers 
have revealed the distinct advantages in signal amplification26,27, narrow linewidth14,28, and strong 
intensity without fluorescence or scattering background29, leading to huge increase in detection 
sensitivity (>100X) and improved signal-to-noise ratios (>1000X) over the fluorescence based 
detection30-32. The significantly enhanced sensitivity and multi-parameter analysis further enables 
us to analyze minute changes in biomolecules, cells, and tissues, with a huge potential for 
biological and medical applications. 
Taking a closer look at the basic principles of optofluidic biolasers, an optofluidic biolaser 
consists of three essential components: (i) a gain medium in the fluidic environment, (ii) an optical 
cavity and (iii) pumping. The photons emitted from the gain medium are trapped by the cavity, 
and the optical feedback induces stimulated emission. When a sufficient number of gain molecules 
in the cavity are excited by pumping, the available gain becomes greater than the total loss in the 
cavity, and laser oscillation builds up. The lasing threshold condition is expressed as 
   ,)()( 01 cae nn    
where n1 and n0 are the concentration of the gain molecules in the excited and ground state, 
respectively. σe and σa are the emission and absorption cross-section of the molecule, respectively, 
at the lasing wavelength λ. γc is the cavity-loss coefficient. Below the threshold, the output through 
the highly reflecting mirror comprises only weak spontaneous fluorescence emission. Above the 
threshold, the output intensity increases dramatically as coherent stimulated emission builds up 
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and grows linearly with the pump energy with a much greater slope than that of fluorescence 
emission6  (see Fig. 1.2).   
The lasing threshold can be reached with sufficient pumping, which relies on several 
parameters, such as the emission cross-section (σe), the concentration of fluorophores (n1) in the 
excited states, the absorption cross-section (σa) ,the cavity loss (γc), and Q-factor of the laser cavity. 
In particular, the Q-factor, or cavity quality factor determines the cavity’s capability to trap photons, 
A higher Q-factor means a lower concentration of gain molecules and lower pump energy are 
required to reach the threshold. In an optofluidic biolaser, these parameters can vary in response 
to specific biomolecular interactions and conformation changes. In turn, monitoring the changes 
in the laser output characteristics such as intensity, spectrum and threshold allows the underlying 
biochemical and biological processes to be revealed. 
To date, optofluidic biolasers have been extensively demonstrated at the molecular level 
for highly sensitive biomolecular detection, including lasing with fluorescent proteins17, DNA33, 
and fluorescent products generated by enzyme-substrate reactions9. In addition, fluorescence 
resonance energy transfer (FRET) lasing has also been successfully demonstrated18 via protein 
pairs, whose lasing efficiencies can be modulated by underlying biological interactions. 
Commercial dye labeled DNA Holliday junction has also shown FRET lasing capability in a bio-
switchable manner34. Recently, biolasers based on single cells using fluorescent proteins 
synthesized directly inside cells or externally added/labeled dyes as the gain medium in-vitro have 
also been accomplished35. Figure 1.3(a) shows the single cellular lasing with green fluorescent 
proteins (gfp) synthesized within the cell when the cells are placed between a FP microcavity. 
Besides using an external cavity, standalone cellular lasers has also been demonstrated by using 
intracellular micro-resonators and suitable optical gain materials36, as shown in Fig. 1.3 (b). These 
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results suggest that the lasing modes can be used to analyze cell structures and gain distribution37-
40. However, all the cellular lasers developed to date are merely a laser embodiment in cells which 
do not carry any biofunctions, i.e., their gain media are not designed to be modulated by (or 
respond to) biological interactions inside cells, and therefore, cannot be used for sensitive 
biosensing35,37. 
 
Figure 1.3. Cellular lasers. (a) Single cellular laser demonstrated by using cell expressed with 
GFP sandwiched between two mirrors (F-P cavity). The lasing spectrum and CCD images of laser 
modes are also shown on the right panel. (b) Intracellular microlasers with fluorescent PS 
micobead in the cell body. Here the microbead serves as the WGM lasing cavity. The second image 
shows the PS bead in green, while the laser emission and spectrum are also given on the right panel.  
1.2.   Motivation for lasing in tissues 
Moving to the next biological hierarchy, detailed characterization of tissues, which consists 
of a collection of cells embedded in extracellular matrix, is generally considered to be more 
practical since it mimics the actual complex biological environment in a living body. As a result, 
lasing in tissue (tissue lasers) is particularly significant for a broad range of applications such as 
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tissue engineering and medical diagnosis. Given that tissue-based lasers have been studied in the 
past by using random laser cavities41-43, the random lasers are incapable of providing repeatable, 
trackable, and precise laser emission signals. Due to the lack of the fixed external cavities. 
Moreover, random lasers are unable to detect biochemical/biological reactions from specific 
targets (e,g., antibodies), as the underlying lasing mechanism is mainly based on the physical 
properties of tissues (inhomogeneities). 
The challenges of tissue lasers described above motivated us to explore and develop an 
analytical platform capable of detection with lasing signals in a biological tissue, which can 
broadly be applied to a variety of targets, tissues, and diseases. Therefore, this thesis is aimed to 
develop optofluidic biolasers consisting of fluorescent biosensors as the gain medium inside tissue, 
which responds to intratissue or intercellular activities for tissue analysis (liquid biopsy and 
surgical biopsy). The unique spectral and spatial characteristics of the laser output will be used to 
better understand minute interactions within tissues with a superior sensitivity and imaging quality 
than fluorescence counterparts. The significance of this thesis is to pioneer a novel on-chip device 
for future medical diagnostics, examination of excised tissues, and image-guided surgery, as well 
as monitoring and differentiating of biological transformations in tissue engineering.  
1.3.   Types of high-Q optical cavities 
In order to develop tissue lasers for various biological and medical applications, different 
types of optical cavities are available. In particular, here we would like to introduce two types of 
high-quality factor (high-Q) micro-cavities which enable us to implement tissue diagnostics for 
liquid biopsy (whole blood, sweat, urine, saliva) and surgical biopsy (excised tumor, skin lesions). 
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For a liquid biopsy, optofluidic ring resonator (OFRR) is an ideal device for optofluidic 
tissue laser as given in Fig. 1.4(a). OFRR is a piece of thin-walled glass capillary waveguide with 
a closed loop44, which supports the circulating resonant waveguide mode or whispering gallery 
mode (WGM) by total internal reflection of light at the curved boundary. The resonant light 
circulates along the OFRR and has evanescent field into the surrounding medium, thus interacts 
repetitively with the liquid or analytes near the resonator surface, to provide the optical feedback 
for biological samples to lase. The intrinsic compatibility with microfluidics and high Q factor of 
OFRR makes it of great advantage to a low lasing threshold while low energy operation is 
particularly important for biological applications. Most importantly, the ring resonator devices 
take the advantage of small footprint, enabling large scale integration to lab-on-chip devices for 
point-of-care diagnostics. 
 
Figure 1.4. Optical cavities for different biopsy samples. (a) Liquid biopsy- whole blood, which 
has high potential for non-invasive molecular disease detection on chip. An optofluidic ring 
resonator which supports WGM lassing is plotted on the right panel. (b) Surgical biopsy- excised 
cancer tissue. An example of FP cavity formed by two high reflectivity dielectric mirrors is plotted 




For a surgical biopsy, Fabry-Pérot (FP) cavities which consist of two highly reflective 
parallel mirrors has advantages regards to the ease of implementation and the planar format45-51, 
as shown in Fig. 1.4(b). Additionally, FP cavity provides a whole-body interaction between the 
electromagnetic field and the gain medium, i.e., a predominant portion of the optical field is within 
the body of the gain medium, in contrast to the evanescent interaction such as in ring resonators. 
This arrangement is particularly important when the gain medium is inside a specific localization 
of cell or tissue. The gain media here can be either cellular networks or solid tissue labeled with 
fluorescent compounds, which are designed to respond to cellular activities, thus producing the 
sensing signal that is then amplified by the laser cavity.  Furthermore, the integration with an 
imaging spectrometer will allow us to accomplish laser emission-based tissue mapping with 
improved spectral resolution and spatial information. 
1.4.   Organization of thesis 
In this thesis, we explored and achieved lasing in several types of tissues by utilizing 
various micro-laser cavities. Furthermore, our work opens the new field to implement laser 
emission in biomedical imaging for improved cancer evaluation. This study marks a critical step 
towards eventual clinical and biomedical applications of optofluidic biolasers, which provides a 
novel tool for on-chip diagnostics in blood, cancer screening, immuno-diagnosis, and better 
understanding of fundamental cell biology.  
For Chapter 2 and 3, lasing in biological tissues by using an optofluidic ring resonator were 
demonstrated. In Chapter 2, we first show optofluidic chlorophyll lasers with intrinsic gain 
medium extracted from leaf, indicating the possibility to lase with natural biological tissues 
(published in Lab Chip, 2016)52. In Chapter 3, we carried out a systematic investigation on ICG 
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lasing in human whole blood, which represents the first optofluidic biolasers using FDA approved 
fluorophores (published in Optica, 2016)30. From Chapter 4 to 6, we developed tissue-based lasers 
with a FP cavity, in which the tissues/cells were sandwiched between two dielectric mirrors. In 
Chapter 4, we demonstrated the first FP tissue laser and its multiplexing capability labeled with 
non-specific fluorophores. We further investigated how the tissue structure/geometry, tissue 
thickness, and staining dye concentration affect the tissue laser (published in Lab Chip, 2017)29. 
Based on the similar concept, Chapter 5 proposes a novel imaging tool for high contrast cancer 
screening and immuno-diagnosis. In Chapter 5, the first scanning-based “laser emission-based 
microscope” (LEM) was developed for improved cancer evaluation by mapping the lasing 
emissions from nuclear biomarkers in human tissues (published in Nature Biomed. Eng., 2017)53. 
Finally, we present an ongoing work in Chapter 6 which shows the potential to monitor living 
biological networks/tissues using laser scheme. Lasing in living neurons and neuronal networks 
with a sub-cellular/single-spike resolution were demonstrated to monitor the intracellular calcium 
dynamics during spontaneous neuronal activities. To conclude, Chapter 7 covers a brief summary 










                                                                                                                    
 
Chapter 2 
Bioinspired Lasers with Chlorophylls from Leaf Tissue 
As the first attempt, we used natural plant leaf tissues to demonstrate the feasibility of optofluidic 
laser in tissue, using intrinsic auto-fluorescent compounds in leaves- chlorophylls, as the gain 
media for lasing (Fig. 2.1(a)). Chlorophylls are essential for photosynthesis and also one of the 
most abundant pigments on earth54,55. Using the optofluidic ring resonator of extremely high Q-
factors (>107), we investigated unique characteristics and revealed the underlying mechanism of 
chlorophyll lasers. The first demonstration of chlorophyll lasers with two lasing bands were 
achieved for the first time in isolated chlorophyll a (Chla). Detailed theoretical analysis, elucidated 
the mechanism that determines when and why the laser emission band appears at one of the two 
bands, or concomitantly at both bands. Finally, Chla was exploited as the donor in fluorescence 
resonance energy transfer with an unprecedented wavelength shift as large as 380 nm.  
2.1. Motivation 
Chlorophylls are not only essential for photosynthesis and genetic engineering, but also 
particularly important for regulating metabolic functions in living organisms54,55. Chlorophyll 
fluorescence has been extensively studied for fundamental understanding of energy transfer 
mechanisms inside chloroplasts56,57. Two bands of emission corresponding to the (0,0) and (0,1) 
vibronic regions of the S1S0 transition are usually observed58,59 , as shown in Fig. 2.1(b). The 
quantum yield of most chlorophylls is approximately 30% 60,61, similar to that of other organic 
dyes such as Cy5, Cy5.5, and Alexa Fluor 647. The strong fluorescent capability of chlorophylls 
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suggests that they can possibly be used as the laser gain medium. In turn, stimulated emission of 
chlorophylls provides insight into the energy transfer processes during photosynthesis. It can also 
be used to better understand the S1 electronic states and interpret fluorescence results (such as 
intensity dependent fluorescence lifetime and quantum yield) 62.  
In comparison with many other laser gain media, chlorophylls are biocompatible and 
biodegradable, making them very attractive in in-vitro and in-vivo sensing applications. 
Meanwhile, the unique dual-absorption bands in the visible spectrum (Fig. 2.1(c)) with extremely 
high extinction coefficients (~105 M-1cm-1 at 430 nm) render chlorophylls excellent light 
harvesting capability to achieve lower lasing thresholds. This characteristic, together with the large 
Stokes shift, suggests that chlorophylls can serve as an excellent donor in a fluorescence resonance 
energy transfer (FRET) laser, which allows implementation of a laser in the red or near infrared 
(NIR) spectrum with blue or ultra-violet (UV) excitation. 
The laser of chlorophylls was briefly studied nearly 40 years ago using a low quality optical 
cavity based on a 1-cm long cuvette62, whose Q-factor (Q) and finesse (F) were only 1.3x105 and 
6, respectively. However, while laser emission at the 680 nm band was observed, which 
corresponds to the (0,1) vibronic region, no laser emission was found around 730 nm and the 
mechanism behind the missing 730 nm band was not fully understood. Here we investigated both 
experimentally and theoretically the optofluidic laser using chlorophyll a as the gain medium and 
a thin-walled glass capillary based optofluidic ring resonator (OFRR, Fig. 2.1(d)) as the laser 
microcavity. The purposes of this work were two-fold. First, we aimed to develop novel 
chlorophyll based optofluidic lasers using chlorophyll as the outstanding gain medium and the 
donor. Second, we took advantage of the extremely high Q-factor (>107) and finesse (F~104) of 




Figure 2.1. Optical properties of chlorophylls. (a) Molecular structure of chlorophyll a (Chla) 
extracted from spinach leaves. (b) Energy level of Chla. S0 stands for ground state, S0 stands for 
the first excited state, and S2 stands for higher excited states. Chla absorbs photons around 430 nm 
and 660 nm, whereas the emission bands at 680 nm and 730 nm in our experiment correspond to 
the (0,0) and (0,1) vibronic regions in the S1S0 transition, which are related to Photosystem II 
and I in chloroplasts, respectively. (c) Normalized absorption and emission spectrum of Chla in 
ethanol. (d) Schematic diagram of the chlorophyll laser using a high Q-factor optofluidic ring 
resonator (OFRR). Green particles represent the chlorophyll molecules dissolved in ethanol. The 
laser was excited by a pulsed optical parametric oscillator (OPO) (wavelength=430 nm). The 
diagram on the right side shows the profile of the OFRR and the whispering gallery mode (WGM) 
circulating along the OFRR circumference. D=80 μm; d=2 μm.  
 
Due to the high Q-factor, a new laser emission band around 730 nm with a lasing threshold 
as low as 8 μJ/mm2 was achieved for 0.1 mM Chla. The second laser emission band around 680 
nm was realized with much higher excitation. In addition, competition between the lasing at the 
680 nm and 730 nm band was observed. It is found that lasing at the 680 nm band can quench or 
significantly reduce the laser emission at 730 nm band, effectively increasing the lasing threshold 
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for the 730 nm band. Further concentration dependent studies, along with the detailed theoretical 
analysis, elucidated the mechanism that determines when and why the laser emission band appears 
at 680 nm or 730 nm, or concomitantly at both wavelengths. Finally, Chla was exploited as the 
donor in FRET to extend the optofluidic laser emission into the near infrared regime with an 
unprecedented wavelength shift as large as 380 nm, respectively and lasing threshold lower than 
0.5 μJ/mm2.  
Our work will open a door to the development of novel biocompatible and biodegradable 
chlorophyll based lasers for various applications such as on-chip tunable coherent light sources 
and in-vitro/in-vivo biosensing. It will also provide important insight into the energy transfer 
process inside plants and help resolve critical issues in plant biology. 
 
2.2. Experimental setup 
The experimental setup of the chlorophyll laser based on the OFRR is illustrated in Fig. 
2.1(d). Here Chla was chosen as the gain medium due to its primary role in photosynthesis.  
Chlorophyll a was purchased from Sigma-Aldrich (Product #C5753). It is known that Chla is 
dissolved in organic solvents, such as ethanol and acetone, not in water 62,63. Therefore in our 
experiments, we chose ethanol as the solvent. Both AF680 and AF700 dyes were purchased from 
Thermo-Fisher (Product #A37574 & Product #A-20110). Each dye (powder) was first dissolved 
in ethanol (99.9%, Sigma-Aldrich) to form a 10 mM solution, and then diluted with ethanol to 
lower concentrations. For FRET lasing experiments, the compound solutions were prepared by 
mixing 10 mM Chla with 10 mM AF680 solutions (and 10 mM AF700 solutions) to achieve the 
desired Chla-AF680 and Chla-AF680-AF700 concentrations. 
In our experiments, Chla was dissolved in ethanol and flowed through the OFRR. The 
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whispering gallery modes (WGMs) circulate along the circumference of the OFRR circular cross 
section (Fig. 2.1(d), right). The evanescent field of the WGM in the OFRR core interacts with the 
gain medium (Chla) and provides the optical feedback for lasing64. Fabrication of the OFRR have 
been well documented elsewhere64-66. Briefly, a fused silica capillary preform (Polymicro 
Technologies TSP700850) was first etched with diluted hydrofluoric acid and then rapidly 
stretched under CO2 laser irradiation. The resulting OFRR capillary was slightly bulged with a 
diameter of 80 μm at the center and of a few microns smaller at the two necking points 
approximately 1 mm apart. The wall thickness of the OFRR was approximately 2-4 μm and the Q-
factor is approximately 107  64,67. A typical confocal optical setup was used to excite the sample 
and collect emission light from the OFRR (Fig. 2.1(d)). In this work, a pulsed OPO laser (pulse 
width: 5 ns, repetition rate: 20 Hz) was used as the excitation source and loosely focused through 
a cylindrical lens (20 mm focal length) to excite a 1-mm portion of the OFRR capillary. The pump 
intensity was adjusted by a continuously variable neutral density filter. The emission light was 
collected through the same lens and sent to a spectrometer (Horiba iHR550) for analysis. 
 
2.3. Results and discussion 
2.3.1. Lasing characteristics   
Fig. 2.2(a) demonstrates the lasing emission spectra of Chla at a concentration of 0.1 mM 
under low pump energy densities. Initially, a number of periodic lasing peaks emerge around 730 
nm. The multiple lasing peaks are the result of multi-mode nature of the WGMs. With the increased 
pump energy density, those lasing peaks grow accordingly, but remain within the same spectral 
range around 730. Fig. 2.2(b) plots the total laser emission in the 730 nm band as a function of the 
pump energy density, from which the lasing threshold is derived to be approximately 8.2 μJ∕mm2. 
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Such a low lasing threshold at a low Chla concentration results from the extremely high Q-factor 
of the OFRR (>107)64,67,68. Lasing emission gradually levels off as the pump intensity is beyond 
110 μJ/mm2. During experiments, the Chla laser at the 730 nm band exhibits high photostability 
when the pump energy density is below 100 J/mm2, suggesting practical use of the Chla laser. 
However, as the pump energy density reaches 250 μJ/mm2, the lasing emission at the 730 nm band 
suddenly vanishes and meanwhile the lasing emission at shorter wavelengths starts to emerge 
around 680 nm. This extraordinary phenomenon can clearly be seen in Fig. 2.2(c) that plots the 
Chla lasing emission spectra under various high pump energy densities. Similar to the lasing 
profile at the 730 nm band, periodic lasing peaks grow but remain consistently within the same 
spectral range with the increased pump energy density. Interestingly, at very high pump energy 
densities, the lasing peaks at the 730 nm band start to re-emerge and compete with those at the 680 
nm band. No other lasing emission bands are observed between the two competing bands. In order 
to better illustrate the competition between the two lasing bands, Fig. 2.2(d) shows the lasing 
profile recorded over a time interval of 15 seconds. Due to conservation of the Chla in the excited 
states, competition in emission between two laser bands can be clearly observed under a constant 
pump energy density. According to our experiments, the corresponding lasing threshold is 
approximately 230 μJ∕mm2 for the laser emission at the 680 nm band.  
The above results reveal important characteristics of chlorophyll lasers. First, there exist 
two separate lasing bands at 680 nm and 730 nm in Chla lasers, which correspond to the (0,0) and 
(0,1) vibronic regions in the S1S0 transition (Fig. 2.1). Second, lasing emission emerges at the 
730 nm band first. With the increased pump energy density, lasing emission at the 680 band 
becomes dominant with concomitant significant reduction in lasing emission at the 730 nm band. 
Third, at very high pump energy densities, lasing emission at the 730 nm band re-emerges and 
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competes with that in the 680 nm band. The above phenomenon is in sharp contrast to the previous 
observation four decades ago62. In that study while the 680 nm lasing band was observed, 
stimulated emission at the 730 nm band was never achieved, even at high chlorophyll 
concentration (2 mM). Although not completely understood, the disappearance of the 730 nm band 
was attributed to the formation of non-fluorescent Chla dimers at high concentrations.  
 
Figure 2.2. Chlorophyll lasing under low and high pump intensity. (a) Lasing spectra of 0.1 
mM Chla in ethanol with relatively low pump energy densities. Curves are vertically shifted for 
clarity. (b) Spectrally integrated laser output as a function of pump energy density extracted from 
the spectra in (a). The solid line is the linear fit above the lasing threshold, showing a laser 
threshold of ~8.2 μJ/mm2. Spectral integration takes place between 728 and 738 nm. (c) Lasing 
spectra of 0.1 mM Chla in ethanol with relatively high pump energy densities. Curves are vertically 
shifted for clarity. (d) Competition emission between two laser bands under a constant pump 
energy density of 326 μJ/mm2. Different colors represent the measured lasing spectra at different 
timing (seconds).  
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2.3.2. Theoretical analysis 
To resolve the contradictory experimental observations and to elucidate the underlying 
lasing mechanisms of Chla lasers, we carried out the following theoretical analysis. At the lasing 













    (1) 
where Tn  is the total concentration of Chla and 1n  is the concentration of the Chla in the excited 
state (S1). )( Le  and )( La   are the Chla emission and absorption cross sections at the lasing 
wavelength (𝜆𝐿),   is the fraction of the light in the evanescent field of the OFRR, 0Q is the OFRR 
empty-cavity Q-factor, and 𝑚 is the effective refractive index of the WGM (m~1.4 for the OFRR). 






















  (2) 
Figures 2.3(a) and (b) plot th values for various representative concentrations of Chla based on 
Eq. (2), in which the absorption and emission cross sections were measured (Fig. 2.3 (c)), under 
the assumption of a high Q-factor (Q0=1x106)67. At relatively high Chla concentrations (Fig. 
2.3(a)), two th minima around 680 nm and 730 nm are found, but th at the 730 nm band is much 
lower than that at the 680 nm band, indicating that the laser emission emerges around 730 nm first. 
Below we use the 0.1 mM Chla in Fig. 2.3(a) as an example to elucidate the Chla lasing mechanism. 
When the excitation is low (Curve 1), no laser emission can be observed. With the increased 
excitation (Curve 2), the 730 nm band is the first to reach the lasing threshold, and consequently, 
lasing emission emerges at this band. When the excitation continues to increase (Curve 3), the 680 
nm band reaches the lasing threshold and starts to lase. Since the number of the excited states is 
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fixed at a given pump energy density, lasing action at the 680 nm band results in quenching or 
significant reduction in lasing emission at the 730 nm, effectively increasing the lasing threshold 
for the 730 nm band. Finally, at very high pump energy density, the laser emission at the 680 nm 
band continues to grow and meanwhile the 730 band laser emission re-emerges and competes with 
the 680 nm band. The above simulation agrees well with the experimental observations in Fig. 
2.2(a) and Fig. 2.2(c). It is interesting to note that laser emission at the 680 nm band can easily 
overtake that at 730 nm, despite the fact that th is lower at 730 nm than at 680 nm. This 
unconventional phenomenon is due to the fact that the (0,1) vibronic band at 680 nm in Chla, 
which is populated first before further relaxation down to the (0,0) vibronic band at 730 nm. Once 
the lasing threshold at the 680 nm band is reached, very rapid population depletion occurs due to 
stimulated emission between S1 and S0, thus making it much more difficult for the 730 nm band 
to achieve population inversion. 
To further understand the lasing mechanism in Chla, in Fig. 2.3(b) we plot th for two very 
low Chla concentrations. Both curves show two minima at 680 nm and 730 nm, respectively. In 
contrast to Fig. 2.3(a), th is lower at the 680 nm than at the 730 nm, indicating that the laser 
emission should occur around 680 nm first and play a dominant role in overall lasing action. At 
low excitation (Curve 4), no lasing emission is expected for either 0.03 mM or 0.01 mM Chla. 
With the increased excitation, 0.03 mM Chla should start to lase at the 680 nm band. When the 
excitation continues to increase (Curve 5), laser emission should be observed at both the 680 nm 
and 730 nm band for 0.03 mM Chla, whereas only laser emission at the 680 nm band can be 
observed for 0.01 mM Chla. Finally, at very high excitation (Curve 6), laser emission from 0.03 
mM Chla continues to increase at both the 680 nm and 730 nm band, whereas only laser emission 




Figure 2.3. Theoretical analysis of chlorophyll laser condition. (a) and (b) Fraction of Chla 
molecules in the excited states needed at the laser threshold for various representative Chla 
concentrations based on Eq. (2) with =0.1 and Q0=107. Curves 1-6 corresponds to various 
excitation levels of Chla molecules. Curve 1: At a very low pump energy density, the Chla 
excitation is quite low. No laser emission is expected to emerge for 0.1 mM Chla. Curve 2: At an 
intermediate pump energy density, the lasing emission at the 730 nm band emerges for 0.1 mM 
Chla. Curve 3: At a relatively high pump energy density, both 680 nm and 730 nm bands emerge 
and compete with each other. Curve 4: At a low pump energy density, the Chla excitation is low. 
No laser emission is expected to emerge for either 0.03 mM or 0.01 mM Chla. Curve 5: At an 
intermediate pump energy density, two lasing bands are expected to appear around 680 nm and 
730 nm for 0.03 mM Chla, and only one lasing band is expected to appear at 680 nm. Curve 6: 
With further increased pump energy density, the lasing emission increases in comparison with the 
case for Curve 5, but no laser emission is expected to appear at the 730 nm band for 0.01 mM Chla 
due to the requirement for extremely high Chla excitation. (c) Absorption cross sections (black 
curve) and emission cross sections (red curve) of Chla in ethanol from 660 nm to 745 nm.  
To validate the above theoretical analysis and simulation results at low Chla concentrations, 
the measured lasing spectra of 0.01 mM and 0.03 mM Chla under different pump energy densities 
are exemplified in Fig. 2.4(a) and (b), respectively. We chose three pump energy densities (65 
μJ/mm2, 250 μJ/mm2, and 580 μJ/mm2) to represent the low, intermediate, and high Chla excitation 
described by Curves 4-6 in Fig. 2.3(b). Note that Curves 4-6 plotted in Fig. 2.3(b) are only 
representatives of different excitation levels and not equivalent to the exact excitation shown in 
Fig. 2.4. Initially, no lasing emission is observed for either 0.01 mM or 0.03 mM Chla, as shown 
by 65 μJ∕mm2 in Fig. 2.4(a) and (b). When the pump energy density reaches 250 μJ∕mm2, two 
lasing bands emerge for 0.03 mM Chla; however, only one lasing band around 680 nm appears for 
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0.01 mM Chla. At 580 μJ∕mm2, laser emission around 680 nm and 730 nm continues to grow for 
0.03 mM Chla. In contrast, for 0.01 mM Chla despite intensity increase in the 680 nm band, no 
laser emission is observed at 730 nm, as it requires much higher pump energy density. The 
experimental observation in Fig. 2.4 matches perfectly the phenomena described in Fig. 2.3(b). 
Based on the above theoretical analysis and experimental observation, it becomes clear that 
there exist two lasing band around 680 nm and 730 nm for Chla. Depending on the Q-factor and 
the Chla concentration, either 680 nm or 730 nm band can start to lase first. In addition, there exists 
competition between the lasing at the 680 nm band and 730 nm band. Lasing at the 680 nm band 
can quench or significantly reduce the laser emission at 730 nm band, effectively raising the lasing 
threshold for the 730 nm band. The reason that the 680 nm overtakes the 730 nm is due to the fact 
that the 680 nm is populated first during the energy transfer process in chlorophylls upon photo-
excitation. Capability to control which band to lase first and observation of the competition 
between the two bands will have significant impact on optofluidic laser development and provide 
vital information to better understand the energy transfer mechanism in Chla.  
Previous work showed lasing emission around 680 nm, but failed to achieve lasing 
emission at the 730 nm band. This was actually due to the low Q-factor cavity (1-cm long cuvette) 
and the competition between the 680 nm and the 730 nm band. Fig. 2.5 plots th for the Chla 
concentration ranging from 0.1 mM to 2 mM with a low Q-factor. It can be seen easily at the 680 
nm band dominates for all concentrations of interest, in particular, at relatively low concentrations 
(0.1 mM – 0.5 mM). At a high concentration of 2 mM, th at the 730 nm is close to that at the 680 
nm band and lasing at 730 nm is seemingly possible. However, due to the competition of the 680 
nm band lasing, the lasing threshold for the 730 nm band is actually much higher than theoretically 
predicted in all concentrations. Furthermore, the penetration depth was only about 200 m at the 
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excitation wavelength of 337.1 nm for 2 mM Chla62, which made the 730 nm lasing emission even 
more difficult to realize for Chla solution in a 1-cm long cuvette. Previous studies attributed the 
disappearance of the 730 nm band lasing to the formation of non-fluorescent Chla dimers at 2 mM, 
which we believe does not reflect the actual underlying mechanism. As a control experiment, 
lasing at the 730 nm band from 5 mM Chla can easily be achieved in Fig. 2.6 with relatively low 
pump energy density using our high Q-factor OFRR. 
 
 
Figure 2.4. Lasing under different concentration and pump energy density. Lasing spectra for 
0.01 mM (a) and 0.03 mM (b) Chla under the pump energy density of 65 μJ/mm2, 250 μJ/mm2, 
and 580 μJ/mm2. The chosen three pump energy densities correspond to the low, intermediate, and 






Figure 2.5. Theoretical analysis of chlorophyll lasing under low-Q factor cavity. Fraction of 
Chla molecules in the excited states needed at the threshold for (a) 0.1 mM, (b) 0.2 mM, (c) 0.5 
mM, and (d) 2.0 mM of Chla based on Eq. (2) in the main text with =1.0 and Q0=1.3x105, which 
corresponds to the situation where a low Q-factor 1-cm long cuvette is used as the laser cavity. In 
all concentrations, the minimum occurs around 680 nm, suggesting that the lasing band at 680 nm 
is dominant. Lasing at the 730 nm band either is non-physical (i.e., n1/nT>1) or requires much 




Figure 2.6. Chlorophyll lasing at 5mM. Lasing at the 730 nm band can be achieved even with 
the Chla concentration as high as 5 mM in ethanol. Curves are vertically shifted for clarity.  
 
2.3.3. Chlorophyll FRET lasing 
In order to further explore the unique properties of chlorophylls such as high absorption at 
blue and UV spectrum and large Stokes shift, we developed and studied an optofluidic chlorophyll 
FRET laser using chlorophyll and dye molecules as the donor and acceptor, respectively. In our 
experiments, Chla and Alexa Fluor 680 dye (AF680) were chosen to be the FRET pair (see Fig. 
2.7 for spectral overlap between Chla and AF680). As a control experiment, Fig. 2.8 shows that 
AF680 alone has a lasing threshold of 31 μJ/mm2. In comparison, Curve 1 in Fig. 2.9(a) shows the 
FRET (Chla+AF680) lasing emission around 780 nm under a very low pump energy density of 
1.1 μJ∕mm2 at 430 nm. Meanwhile, only featureless emission spectra are observed for Chla and 
AF680, as exemplified in the Curve 2 and Curve 3, respectively. Therefore, the lasing emission at 
780 nm at 1.1 μJ∕mm2 is from AF680 under FRET excitation, which extends the lasing emission 
to the NIR. We further investigated the FRET laser emission spectra at different pump energy 
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densities, as shown in Fig. 2.9(b). A significant blue-shift of the FRET lasing peaks is observed as 
the pump intensity increases, which is typical for dye lasers67. Note that at 38 J/mm2, the AF680 
alone can lase through direct excitation at 430 nm (see Fig. 2.8). However, such laser emission 
(around 780 nm) can be easily distinguished from that via FRET (around 750 nm in Fig. 2.9). The 
spectrally integrated FRET emission versus pump energy density for Chla-AF680 is plotted in Fig. 
2.9(c), in which the lasing threshold is derived to be as low as 0.7 μJ∕mm2 from the inset, which is 
40 times lower than that of AF680 alone. 
 
Figure 2.7. Absorption and emission spectra for FRET. (a) Normalized absorption (dashed line) 
and emission (solid line) spectrum of Chla (Curves 1 and 2), AF680 (Curves 3 and 4), and AF700 
(Curves 5 and 6) in ethanol. 
 
In order to extend the laser emission further into the NIR, a third dye (Alexa Fluor 700 - 
AF700) was used in conjunction with Chla and AF680 (see Fig. 2.7 for the spectral overlap among 
Chla, AF680, and AF700) to form a cascade FRET laser, in which the pump energy is first 
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absorbed by Chla, subsequently transferred to AF680, and finally to AF700. Curve 1 in Fig. 2.9(d) 
shows the cascade FRET laser emission from AF700 at a pump energy density of 0.8 μJ∕mm2. 
Multiple lasing peaks around 810 nm, which represent a spectral shift over 380 nm, are obtained. 
Further pump energy density dependent experiment in Fig. 2.10(a) shows that the lasing threshold 
is approximately 0.5 J/mm2. To confirm the laser emission was indeed from AF700 via cascade 
FRET, two control experiments were carried out. Curve 2 in Fig. 2.9(d) shows no laser emission 
from AF700 in the absence of AF680 due to insufficient energy transfer between Chla and AF700 
caused by small spectral overlap. Curve 3 further shows that no laser emission from AF700 alone 
at 0.8 μJ∕mm2, since its lasing threshold is 1.8 J/mm2 (Fig. 2.10(b)), 3.6 times higher than that 
obtained in Curve 1. Finally, to demonstrate the versatility of the cascade FRET laser, in Fig. 2.11 
we replaced AF700 with DyLight 700 (Dyl700) and achieved laser emission around 810 nm. 
 
 
Figure 2.8. Direct lasing of AF680. (a) Lasing spectra of AF680 (5 mM) alone in ethanol under 
various pump energy densities. Excitation wavelength=430 nm. (b) Spectrally integrated (745 nm 
– 790 nm) laser output as a function of pump energy density extracted from (a). Solid line is the 








Figure 2.9. Two-level and three-level chlorophyll FRET lasing. (a) Comparison of the lasing 
spectra of mixture of Chla-AF680 in ethanol (Curve 1), Chla alone in ethanol (Curve 2), and Alexa 
Fluor 680 (AF680) alone in ethanol (Curve 3) under the same pump energy density of 1.1 μJ/mm2. 
(b) Lasing spectra of AF680 in ethanol via energy transfer from Chla under various pump energy 
densities. In (a) and (b), [Chla]=5 mM  and [AF680]=5 mM for all curves. Excitation 
wavelength=430 nm. (c) Spectrally integrated (745 nm – 790 nm) FRET laser output as a function 
of pump energy density extracted from (b). The inset presents the enlarged portion for the pump 
energy density below 3.0 μJ/mm2. Solid lines are the linear fit, showing a lasing threshold of 
approximately 0.7 μJ/mm2. (d) Emission spectra of mixture of Chla-AF680-AF700 (1), mixture 
of Chla-AF700 (2), and Alexa Fluor (AF700) dye alone (3) under the same pump energy density 
of 0.8 μJ/mm2. [Chla]=5 mM, [AF680]=5 mM, and [AF700]=5 mM for all curves. Curves are 




Figure 2.10. Lasing threshold of three-level FRET and pure AF700. Spectrally integrated (800 
nm – 825 nm) laser output as a function of pump energy density of (a) cascade FRET laser 
emissions (CHla+AF680+AF700) and (b) AF700 laser emissions. Solid line is the linear fit above 
the threshold, showing a lasing threshold of approximately 0.5 μJ/mm2 and 1.8 μJ/mm2, 





Figure 2.11. Lasing spectra of Chla-AF680-Dyl700 FRET. Emission spectra of mixture of Chla-
AF680-Dyl700 in ethanol (Curve 1), mixture of Chla-Dyl700 in ethanol (Curve 2), and Dyl700 
alone in ethanol (Curve 3) under the same pump energy density of 3.4 μJ/mm2. [Dyl700]=5 mM, 




2.4  Conclusion 
We have investigated the chlorophyll based optofluidic laser, in which two competing 
lasing bands at the 680 nm and 730 nm were observed for the first time. The lasing threshold for 
the 730 nm as low as 8 J/mm2 was achieved for 0.1 mM Chla. Furthermore, we found that the 
lasing emission at the 680 nm band results in the quenching or significant reduction in the lasing 
emission at the 730 nm, effectively increasing its lasing threshold. The theoretical analysis and 
experimental measurement revealed the detailed mechanism that determines when and why the 
laser emission band appears at 680 nm or 730 nm, or concomitantly at both wavelengths. In 
addition, using Chla as the donor, we have achieved FRET laser at the NIR with a wavelength shift 
as large as 380 nm. 
We envision that our work lead to the development of novel biocompatible optofluidic 
devices and optofluidic FRET lasers with low lasing thresholds and large wavelength shifts. The 
ability to control the laser emission band will enable us to engineer and optimize optofluidic lasers 
for various applications. Our work may offer scientists to resolve critical issues in plant biology, 













Lasing in Human Whole Blood 
In this chapter, we first demonstrate optofluidic lasers in tissues by using liquid biopsy, including 
human serum and whole blood. Here we utilized Indocyanine green (ICG) as the gain material for 
lasing in tissues. ICG is the only near-infrared dye approved by the U.S. Food and Drug 
Administration for clinical diagnosis of cancer. Here we successfully demonstrated the first ICG 
lasing in human serum and whole blood with the clinical ICG concentrations and the pump 
intensity far below the clinically permissible level. Furthermore, we systematically studied ICG 
laser emission within each major serological components and revealed the critical conditions for 
lasing. Detailed blood components that are investigated in this chapter are plotted in Fig. 3.1(a). 
3.1. Introduction 
ICG is the only near-infrared dye approved by the U.S. FDA for clinical use 70,71, such as 
hepatobiliary surgery 72, sentinel lymph node biopsy 73, and assessment of surgical tumor resection 
margins 70,74. ICG has low toxicity and exhibits absorption and emission maxima around 730 nm 
and 800 nm (Fig. 3.1(b)) - both wavelengths are within the ideal spectral window of human tissues 
for clinical imaging. When injected in blood, ICG binds primarily to plasma proteins and 
lipoproteins, resulting in enhanced fluorescence 70,75-78 (as shown in Fig. 3.1(c)). In practice, ICG 
is injected in the blood circulation within the normal clinical dosage range to locate the tumor site 
and its margin by the higher fluorescence above the background since more blood vessels are 
grown within/around the tumor site 79,80. In addition, ICG has been extensively used in in-vitro 
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preclinical studies of cell lines or animal tissues77,80-82 with an aim to develop innovative 
technologies and methodologies for potential clinical applications. In cancer surgery, one of the 
main prognostic factors for survival rate is complete tumor resection and imaging modalities that 
allow the specific differentiation and identification of vital structures, would be of huge benefit 
during image guided surgery. However, in clinical applications, due to background fluorescence 
and omnipresent tissue scattering, it remains challenging to obtain high contrast in ICG emission 
between the tumor and normal tissue for precise tumor detection and margins of excision81,83-85. In 
in-vitro applications, ICG emission is often not sensitive enough to detect or monitor subtle 
changes in concentrations or structures in biomolecules, cells, and tissues. Therefore, ICG 
emission with a superior signal-to-background ratio (SBR) is highly desirable. 
As discussed in chapter 1, laser emission has distinct advantages over fluorescence, 
particularly at the molecular 6,9,23,27,52,86,87 and cellular level 6,20,35,36. First, it is significantly more 
sensitive to biomolecular and cellular changes than fluorescence 6,23,86-88, thanks to the optical 
feedback in lasing. Second, the laser signal is orders of magnitude stronger and has much narrower 
linewidth (so that the broad-band background can be spectrally filtered out). Finally, due to the 
threshold behavior in lasing emission, a large contrast (102-103 fold) can be obtained between 
before and after lasing 27,89. All of those result in unprecedented SBR in imaging for tumor 
localization and sensitivity in in-vitro biosensing. Therefore, using ICG laser emission could lead 
to a paradigm change in clinical practice and theranostics. However, while a plethora of previous 
work have shown the great promise of  optofluidic lasers in in-vitro biomolecular and cellular 
analysis 6,18,23,27,35,36,87-89, no research has been conducted on feasibility of laser emission from an 
FDA approved dye in whole human blood (which is tissue), particularly at the clinically acceptable 





Figure 3.1.  Concept of whole blood and ICG emission properties. (a) Schematic diagram 
showing the composition of blood. The diagram on the rightmost column lists the serological 
components along with their respective typical concentrations in serum, which we have 
investigated in the current work. Green checks denote that lasing was achieved with those 
components when Indocyanine Green (ICG) within the clinically acceptable concentration range 
was added, whereas the red cross denotes the component that no lasing was observed from ICG.  
(b) Normalized absorption spectrum (blue curve) and emission spectrum (red curve) of purified 
ICG in DI water from 660 nm to 880 nm. (c). Emission spectra of ICG in water (green curve), ICG 
in ethanol (blue curve), ICG with BSA (0.6 mM) in PBS (red curve), ICG with HSA (0.6 mM) in 
PBS (purple curve), and background signal (black curve) under the same pump energy density. 
Excitation wavelength=660 nm. The ICG concentration was fixed at 0.2 mM for all measurements. 
To estimate the quantum yield (QY), we used the well-known QY of ICG in ethanol (13.2%) as 
the reference. The measured QY is 0.48% for ICG alone in water, 4.1 % for ICG-HSA, and 3.9 % 
for ICG-BSA.  
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In this chapter, we carried out for the first time systematic investigation on ICG lasing. We 
started with each of major serological components (albumins, globulins, and lipoproteins) to 
elucidate the critical elements and conditions responsible for ICG lasing. Then, we demonstrated 
ICG lasing in human serum. Finally, we studied ICG lasing in human whole blood. All the ICG 
concentrations in serological component studies were well below the commonly used level in in-
vitro biological studies (~1 mM) 90-92 with the lasing threshold on the order of 1 μJ/mm 2. More 
significantly, lasing could be achieved in human serum and whole blood using ICG within the 
normal range of clinical dosage (0.01 mM – 0.07 mM in human blood 93,94). The threshold of laser 
emission in whole blood was 10 μJ/mm2, 20 times lower than the laser exposure limit for tissues 
(~200 μJ/mm2) 95. In the end of the Chapter, we will present a few possible clinical, preclinical, 
and biomedical opportunities where the ICG laser may help improve the existing practices and 
also discuss the challenges that it faces, in particular, for in-vivo clinical applications where the 
current high-Q cavities may not be applicable.  
3.2. Experimental design 
 
Throughout the experiments, we used the optofluidic ring resonator (OFRR) based on a 
thin-walled fused silica capillary, as illustrated in Fig. 3.2(a). The circular cross section of the 
capillary forms the ring resonator that that supports the high-Q (>107) whispering gallery modes 
(WGMs). The liquid was injected into the OFRR, in which the evanescent field of the WGM 
present inside the capillary interacts with gain medium in the liquid and provides the optical 
feedback for lasing.  
The ICG used in this work was purchased from Sigma-Aldrich (Product #C5753). Other 
components including HSA (P8119), LDL (L8292), γ-globulins (G4386) and human serum 
(H4522) were all purchased from Sigma-Aldrich. BSA and PBS were purchased from R&D 
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systems (Product#841380, #896009). Human whole blood was purchased from ZenBio Inc. 
(Product# SER-WB10ML), which were collected from healthy volunteers (1 male and 1 female) 
through Interstate Blood Bank, USA. First, ICG powder was dissolved in DI water to form 2 mM 
solution, and then diluted with DI water to lower concentrations (1 mM and 0.2 mM). LDL, BSA, 
HSA and human serum were originally ordered in solution form, whereas γ-globulins powder was 
prepared by dissolving it in 0.9% saline. The measured concentration of LDL, BSA and HSA in 
this work were diluted by mixing with 2 mM, 1 mM, or 0.2 mM ICG solutions to obtain  the desired 
compound solutions. For the serum experiments, 200 μL of pure serum was mixed with 50 μL of 
ICG (1 mM, 0.2 mM) to obtain ICG (0.2 mM, 0.04 mM) compound solutions, respectively. 
Regarding the whole blood experiments, fresh human blood was first diluted two times with PBS, 
then added with 0.2 mM ICG to form 0.04 mM compound solution. Other concentrations of ICG 
used in experiments were prepared similarly. All the prepared samples were allowed to stand for 
20 minutes under room temperature before measuring to ensure the completion of binding 
reactions of ICG. 
The fabrication of the OFRR have been well documented elsewhere 64. The resulting OFRR 
capillary was slightly bulged with a diameter of 80 μm at the center and of a few microns smaller 
at the two necking points approximately 1 mm apart. The wall thickness of the OFRR was 
approximately4 μm and the Q-factor is approximately 107  64,67.  
Similar to Chapter 2, a typical confocal setup was used to excite the sample and collect 
emission light from the OFRR (Fig. 3.2(c)). A pulsed OPO laser (pulse width: 5 ns, repetition rate: 
20 Hz) with 660 nm was used as the excitation source to excite a 1-mm portion of the OFRR 





Figure 3.2. Experimental setup and ICG lasing. (a) Schematic of the ICG laser using a high Q-
factor optofluidic ring resonator (OFRR). It also illustrates that the ICG lasing can only be achieved 
when ICG binds to serological components such as albumin and lipoprotein. The green circles 
denote ICG molecules, whereas the red circles denote serological components. During the 
experiment, ICG was excited by a pulsed optical parametric oscillator (OPO) (pulse width=5 ns; 
wavelength=660 nm). (b), Comparison among various emission spectra of ICG. Curve 1: ICG 
alone in PBS. Curve 2: ICG alone in DI water. Curve 3: ICG with albumin (BSA) in PBS.  All 
curves were obtained under the same pump energy density of 4.8 μJ/mm2 with the same ICG 
concentration of 0.4 mM. Curves are vertically shifted for clarity. (c) Illustration of the 
experimental setup. The right photo shows the experimental setup. The red line indicates the 





3.3. Results and discussion 
3.3.1. Indocyanine green (ICG) lasing 
First, as a control experiment, Curves 1 and 2 in Fig. 3.2(b) show no laser emission from 
ICG (0.4 mM) alone in either phosphate buffered saline (PBS) or deionized (DI) water at the 
excitation of 4.8 μJ/mm2. In fact, no laser emission was observed even when the excitation was as 
high as 25 μJ/mm2. This is due to the extremely low quantum yield (0.48%) of ICG in PBS or 
water. In contrast, in the presence of proteins rapid binding to ICG results in a significant increase 
in quantum yield (~4.0 %, Fig. 3.1). Although such a quantum yield is still quite low in comparison 
with that for many other dyes (such as Rhodamine 6G, Cy3 and Cy5, etc.), it is sufficient to support 
laser emission. In turn, since laser emission is stimulated emission, which process is much faster 
than many non-radiative recombination processes, the quantum yield becomes significantly 
enhanced once the lasing threshold is achieved. Curve 3 in Fig. 3.2(b) displays the first 
demonstration of the ICG lasing with bovine serum albumin (BSA, 1.2 mM) in PBS under the 
same excitation as Curves 1 and 2. Strong laser emission peaks emerge on the red side of the ICG 
fluorescence spectrum (900 nm – 935 nm). The linewidth of each peak is approximately 0.18 nm, 
limited by the resolution of the spectrometer. Those lasing peaks exhibit an SBR as high as 800, 
nearly 20-fold improvement over that obtained with the fluorescence based measurement with the 
same BSA-ICG mixture under the same excitation (Fig. 3.1(c) shows a SBR of 40 for ICG-BSA 
fluorescence vs. background), attesting to the advantage of using laser emission in  accurate 
determination of tumor boundaries and sensitive measurement analyte concentration changes 87.  
In order to comprehensively understand the ICG lasing for prospective clinical and 
preclinical applications, we first studied the ICG lasing behavior of  albumin, globulin and 
lipoprotein (Fig. 3.1(a)) with the ICG concentration well below the commonly used level in in-
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vitro biological studies 91, as described in section 3.3.2.  
3.3.2. Lasing with serological components 
Albumins 
As presented in Fig. 3.3, we investigated the ICG laser under different albumin/ICG molar 
ratios (Figs. 3.3(a-c)) and various ICG concentrations (Figs. 3.3(d-g)). Bovine serum albumin 
(BSA) in PBS was used as our model albumin, since it is the most abundant protein in blood 
plasma. We used five solutions with the molar ratio of BSA:ICG ranging from 2:1 to 3.3:1 while 
fixing the ICG concentration (0.4 mM). Fig. 3.3(a) presents the lasing spectra for different 
BSA/ICG molar ratios under the same excitation. Detailed studies reveal that different BSA/ICG 
ratios resulted in different lasing thresholds, as shown in Figs. 3.3(b) and 3.3(c), with a minimal 
lasing threshold of 0.38 μJ/mm2 for a molar ratio around 3:1. This phenomenon suggests that the 
ICG binding efficiency (or activation efficiency) plays an important role in ICG lasing. Indeed, in 
Fig. 3.4 we carried out regular fluorescence measurement with various BSA/ICG ratios. At a low 
BSA/ICG ratio, the fluorescence is relatively weak, suggesting that not all ICG molecules are 
activated (i.e., bound to BSA molecule). When BSA/ICG=3, nearly all ICG molecules are bound 
to BSA and the fluorescence starts to saturate. Here our fluorescence results not only correlate well 
with our laser experiments, but also are consistent with a recent finding that a BSA molecule can 
bind at most one ICG molecule at a time 96,97. Note that the slight reduction in fluorescence (and 
hence increase in the ICG lasing threshold) when excessive amount of BSA was added may be 




Figure 3.3. ICG lasing with bovine serum albumins. (a), Lasing spectra of ICG bound to 
albumin (BSA) with different molar ratios (BSA:ICG varying from 2:1 to 3.3:1)). All curves were 
obtained at the same concentration of ICG (0.4 mM) and same pump energy density of 1.4 μJ/mm2. 
Curves are vertically shifted for clarity. (b) Spectrally integrated (900 nm – 930 nm) laser output 
as a function of pump energy density extracted from the spectra in a. The solid lines are the linear 
fit above the lasing threshold. (c) Lasing threshold as a function of the BSA:ICG molar ratio 
extracted from the linear fit in b. The minimum threshold of 0.38 μJ/mm2 was observed around 
3:1. The dashed curve is a quadratic fit to guide an eye. (d-f) Lasing spectra of 0.4 mM ICG (d), 
0.2 mM ICG (e), and 0.04 mM ICG (f) bound to BSA under various pump energy densities. 
Multimode lasing with irregular spacing was observed as pump intensity increases. All curves in 
d-f were obtained with the same BSA:ICG molar ratio of 3:1.  Curves are vertically shifted for 
clarity. (g) Spectrally integrated (900 nm – 930 nm) laser output as a function of pump energy 
density extracted from the spectra in d-f. The threshold based on the linear fit (solid lines) is 
approximately 0.4 μJ/mm2, 2.3 μJ/mm2, and 5.3 μJ/mm2, respectively, for 0.4 mM, 0.2 mM, and 




Figure 3.4. Fluorescence emission of ICG with different BSA ratios. (a) Fluorescence emission 
spectra of ICG in different concentrations of BSA. The concentration of ICG was fixed at 0.2 mM. 
The BSA/ICG ratio varied from 0.75 to 3.8. (b) Normalized fluorescence intensity as a function 
of the BSA/ICG molar ratio extracted from the peak value in (a). The red dashed curve shows the 






Figure 3.5. ICG lasing with human serum albumins. (a) Lasing spectra of ICG (0.2 mM) with 
Human Serum Albumin (HSA) under various pump energy densities. Curves are vertically shifted 
for clarity. (b) Spectrally integrated (900 nm – 920 nm) laser output as a function of pump energy 
density extracted from (a). Solid line is the linear fit above the threshold, showing a lasing 




To study the concentration dependency of the ICG lasing, Figs. 3.3(d-f) show the lasing 
spectra of three ICG concentrations at 0.04 mM, 0.2 mM and 0.4 mM, respectively, when the 
BSA/ICG ratio was fixed at 3:1. The corresponding lasing threshold curves are plotted in Fig. 
3.3(g), showing the decreased threshold with the increased ICG concentration, which is typical for 
an optofluidic laser 67. Even with the lowest ICG concentration (0.04 mM), the lasing threshold 
was only 5.3 μJ/mm2. To mimic human plasma, we replaced BSA with human serum albumin 
(HSA) (fluorescence spectrum in Fig. 3.1(c)). Once again, a low lasing threshold of 1.68 μJ/mm2 
was obtained when ICG (0.2 mM) binds to HSA (0.6 mM) (Fig. 3.5). The slightly lower lasing 
threshold for HSA than for the BSA counterpart (2.3 μJ/mm2) is due to the relatively high binding 
affinity of ICG to HSA 96 (hence the ICG quantum yield) as well as the red-shifted fluorescence 
(and the gain) spectrum (see Fig. 3.1(c)). 
Globulins 
Next, we studied globulins (GLBs), which take up nearly 35% of the plasma proteins. We 
used three different concentrations (0.1 mM, 0.2 mM and 0.3 mM in saline) of γ-GLB (one type 
of GLBs in blood) to cover the clinically relevant globulin concentration (~0.25 mM). The ICG 
concentration was fixed at 0.2 mM. However, no lasing emission could be observed even at a high 
excitation of 25 μJ/mm2 (Fig. 3.6). Given that globulins have been reported to bind ICG molecules 
in previous papers 75,98-100, our result is surprising that GLB is unable to produce lasing. In Fig. 3.7, 
we investigated the cause of such negative results and discovered that the quantum yield of ICG 
when bound to GLB (~0.56%) is not as high as generally thought. It is actually about 7 times lower 




Figure 3.6. ICG lasing with globulins.  Emission spectra of the mixture of ICG (0.2 mM) and γ-
globulins of different concentrations. All curves were pumped under a pump energy density of 25 
μJ/mm2. In human, the average concentration of γ-globulins was approximately 0.25 mM, within 




Figure 3.7. Fluorescence emission of ICG with globulins. Emission spectra of ICG with γ-
globulins (0.1 mM) (blue curve) and ICG with γ-globulins (0.3 mM) (red curve), compared to ICG 
with BSA (0.6 mM) under the same pump energy density. The ICG concentration was fixed at 0.2 




Besides plasma proteins, lipoproteins are another major serological component. 
Lipoproteins are complex particles that carry lipids such as triglycerides and cholesterol through 
the bloodstream. They are simply classified into high-density (HDL) and low-density (LDL) 
lipoproteins, in which LDL level is regarded as a critical criterion for cardiovascular diseases. To 
determine whether ICG binds to lipoproteins and generates lasing emission, we investigated LDL 
in PBS with a concentration matching that in human blood (~0.01 mM). The ICG concentration 
was fixed at 0.2 mM. In Fig. 3.8(a) we present the lasing emission spectra for LDL pumped under 
various pump energy densities. Compared to ICG lasing for albumins (center around 920 nm), 
lasing peaks for LDL emerged at longer wavelengths (around 930 nm) due to the red-shift of the 
ICG-LDL fluorescence (hence the gain) profile (see Fig. 3.9). Further pump energy density 
dependent experiments in Fig. 3.8(b) show a remarkably low threshold of only 0.17 μJ/mm2, which 
is over 10X lower than the corresponding ICG-BSA lasing (threshold = 2.3 μJ/mm2 given in Fig. 
3.3(g)) and ICG-HSA lasing (threshold = 1.68 μJ/mm2  given in Fig. 3.5) that have the same ICG 
concentration (0.2 mM). Such a low threshold can be accounted for by the higher gain 
(proportional to the quantum yield, which is 12.8 % for ICG-LDL) of ICG-LDL than that of ICG-
BSA and ICG- HSA. 
The above result becomes even more significant when we consider that the LDL 
concentration (0.01 mM) used was 60 times lower than BSA and HSA (0.6 mM). Previously it 
was thought that albumins are responsible for enhanced fluorescence in blood 77,98,101. However, 
recent studies revealed that ICG might bind mainly to lipoproteins 71,77,97,102,103. Indeed, our 
fluorescence measurement shows that lipoproteins bind more ICG and produce approximately 3 




Figure 3.8. ICG lasing with lipoproteins. (a) Lasing spectra of ICG bound to low-density 
lipoprotein (LDL) under various pump energy densities. The respective concentration of ICG and 
LDL was 0.2 mM and 0.01 mM, respectively. Curves are vertically shifted for clarity. (b) 
Spectrally integrated (920 nm – 940 nm) laser output as a function of pump energy density 




Figure 3.9.  Absorption and emission spectra of ICG with lipoproteins. (a) Comparison of the 
emission spectra of ICG with LDL (0.01 mM) and ICG with BSA (0.6 mM) shows that the QY 
for ICG with LDL is approximately 12.8%. (b) Normalized absorption spectra of ICG with LDL 
(0.01 mM) and ICG with BSA (0.6 mM). The absorption peak at 750 nm is due to ICG molecules, 
whereas the strong absorption at UV wavelengths is due to the intrinsic absorption of proteins and 




albumin concentrations. Our lasing experiment offers another evidence to support the above 
finding. Furthermore, this suggests that we can obtain the ICG lasing for lipoproteins well before 
for albumins, thus providing a unique means to sensitively monitor lipid levels in blood. In fact, 
due to the threshold behavior, the signal difference between ICG-lipoprotein (lasing emission) and 
ICG-albumin (fluorescence) can be as high as 100-1000 times 27,87,89, orders of magnitude larger 
than the 3 times difference in the conventional fluorescence measurement.  
Serum 
Moving a step forward, we explored the ICG lasing possibility in human serum, which 
contains abundance of plasma proteins, lipoproteins, antibodies, hormones and antigens. As a 
control experiment (Fig. 3.10(a)), no lasing emission was observed from serum itself. In contrast, 
as we added ICG (0.2 mM) into serum, lasing emission could easily be observed (Fig. 3.11(a)). 
The lasing threshold is 0.45 μJ/mm2 (Fig. 3.11(b)), falling between that of HSA and LDL, as ICG 
molecules bind to both plasma proteins and lipoproteins. We also measured serum by using ICG 
with a concentration as low as 0.04 mM, lasing was obtained with a threshold of 3.4 μJ/mm2.  
 
Figure 3.10. Control experiment of lasing with serum and blood. (a) Comparison of the lasing 
spectra of serum alone and serum mixed with ICG (0.04 mM) under pump of 10 μJ/mm2. (b) 
Comparison of the lasing spectra of human whole blood alone and whole blood mixed with ICG 





Figure 3.11. ICG lasing with human serum. (a) Lasing spectra of ICG bound to human serum 
under various pump energy densities. The concentration of ICG was 0.2 mM. Curves are vertically 
shifted for clarity. (b) Spectrally integrated (920 nm – 940 nm) laser output as a function of pump 




3.3.3. Lasing in whole blood 
Our work culminated in achieving direct lasing from “whole blood”. As a control 
experiment, we first flowed human whole blood (2X diluted in PBS to avoid clogging) through 
the OFRR as illustrated in Fig. 3.12(a). Upon excitation, no lasing emission was observed even at 
a high excitation of 25 μJ/mm2 (Fig. 3.10(b)). In contrast, when ICG (0.04 mM) mixed with human 
whole blood (2X diluted in PBS to avoid clogging), the lasing band emerged at 915 nm (Fig. 
3.12(b)). The spectrally integrated laser emission versus pump energy density for blood with ICG 
is presented in Fig. 3.12(c), in which the lasing threshold is derived to be approximately 10 μJ∕mm2. 
The relatively high lasing threshold results from the relatively low concentration of plasma 
proteins and lipoproteins in whole blood as compared to that in the serum in our previous studies. 
Moreover, blood cells and other serological components cause disturbance in the gain media, 
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which could significantly degrade the OFRR Q-factor. Nevertheless, this lasing threshold is still 
>20X lower than the current standard for clinical surgery 95, which is considered to be bio-safe and 
noninvasive. 
Fig. 3.12(d) presents the ICG concentration dependent study of the “blood lasing” under the 
same pump intensity of 20 μJ/mm2. The ICG concentration ranged from 0.01 mM to 0.06 mM, 
which is within the normal ICG clinical dosage allowed in the circulation system of a human body. 
Again the blood sample was 2X diluted. As shown in the black curve of Fig. 3.12(d), only 
featureless emission was observed for 0.01 mM ICG. The most prominent blood lasing was 
achieved when the ICG concentration was around 0.035 mM to 0.04 mM. However, the laser 
intensity began to drop dramatically when ICG was higher than 0.06 mM and no laser emission 
was observed beyond. 
Our concentration dependent laser emission results are consistent with the previous studies 
on fluorescence, which show that strong fluorescence is observed when the ICG concentration is 
0.04 mM to 0.08 mM 104. The maximum intensity around 0.065 mM indicates a critical point at 
which nearly all binding sites in whole blood are occupied by ICG molecules. As such, the 
fluorescence begins to decrease as the ICG concentration increases beyond 0.065 mM, which can 
be attributable to two possible factors, i.e., the increased absorption from excessive unbound ICG 
molecules and the self-quenching effect of ICG molecules 105. Note that the two times difference 
in the optimal ICG concentration between lasing (0.035-0.04 mM) and regular fluorescence (0.065 





Figure 3.12. ICG lasing with human whole blood. (a) Schematic showing the excitation process 
of human whole blood flowing through an OFRR. RBC: red blood cell; WBC, white blood cell 
(leukocytes). (b) “Blood” lasing spectra under various pump energy densities when ICG (0.04 mM) 
were injected into the OFRR along with real human whole blood (2x diluted with PBS buffer to 
avoid clogging). Curves are vertically shifted for clarity. (c) Spectrally integrated (900 – 930 nm 
laser output as a function of pump energy density extracted from the lasing spectra. (d) 
Concentration dependent study of the “blood” lasing with various ICG concentrations (0.01 mM 
– 0.06 mM) in human whole blood (2X dilution with PBS buffer to avoid clogging). A red shift is 
observed as the pump increases. No lasing emission was observed when the ICG concentration 
was above 0.06 mM. The pump energy density was fixed at 20 μJ/mm2. Curves are vertically 






In this work, we demonstrated the first “blood laser” using the only FDA approved near 
infrared dye, ICG, in human whole blood with the dye concentration within the clinically 
acceptable range. In addition, we also investigated the ICG lasing behavior in three major 
serological components (albumins, globulins, and lipoproteins) using the ICG concentration lower 
than the typical concentration used in in-vitro studies on cells and excised tumor tissues. In all 
studies, the pump intensity is orders of magnitude lower than the exposure level that may cause 
damage to cells or tissues. Furthermore, we found that it is albumins and lipoproteins that are 
responsible for ICG lasing and that lipoproteins are far more effective than albumins in achieving 
ICG lasing. 
Our work opens a door to a broad range of clinical and biomedical applications in-vivo and 
in-vitro that provide superior sensitivity and imaging quality than fluorescence counterparts, such 
as in-vitro examination of excised tumor tissues, in-vitro diagnostics in whole blood (cancer cell 
detection and monitoring of lipid in blood), in-vivo tumor margin determination during surgery, 
preclinical research applications, and single cellular bioanalysis, just to name a few. Together with 
the recent advancement in optofluidic cellular lasers 6,20,35,36, lasing in whole blood (which is tissue 
and generally considered to be closer to actual complex biological samples than cells) represents 
a critical step towards eventual clinical applications of optofluidic lasers.  
As an outlook, below we present a few clinical, preclinical, and biomedical scenarios where 
the ICG laser may be implemented, and discuss the challenges it faces. (1) Image guided surgery 
and screening. In this scenario, the ICG is first administered to patients, and then the suspected 
tumor is removed and examined under a fluorescence microscope. As discussed previously, ICG 
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lasing may help improve differentiation and identification of vital structures in tissues. To 
implement, a high-Q Fabry-Perot cavity (the Q-factor is as high as 6x105 106, close to that of the 
OFRR used in the current work) can be employed for in-vitro biological imaging and spectroscopy 
due to its planar format. (2) In-vivo characterization and differentiation of tissues. In this scenario, 
macroscopic laser cavities such as Fabry-Perot cavities and ring resonators discussed above may 
not be applicable. In contrast, the random laser 42,107 and plasmonic laser 108 offer a possible tool 
to realize lasing at the microscopic and nanoscopic scales. However, it should be noted that those 
types of laser cavities usually have much lower Q-factors, which may require higher ICG 
concentrations and pump intensities. Therefore, more work needs to be carried out in the future to 
develop cavities that are compatible with in-vivo tissues and have relatively high Q-factors. 
Meanwhile, new methods that can deliver higher concentration of ICG, which helps lower the 
pump intensities required for lasing, while maintaining clinical safety, should also be investigated. 
One example in this regard is high concentrations of ICG encapsulated in clinically compatible 
nanoparticles applications recently demonstrated 109,110. (3) Hyperspectral imaging. It has shown 
the great potential by combining laser spectroscopy with imaging, thereby providing both higher 
spectral/spatial information and image contrast 84,85,111. The ICG lasing presented in this chapter 
will also lead to the development of novel hyperspectral imaging technologies that complement 










Versatile Tissue Lasers for Multiplexed Detection 
Besides lasing with liquid biopsy (Chapter 3), here in Chapter 4 we developed a highly versatile 
tissue laser platform, in which tissue biopsy stained with fluorophores are sandwiched in a high-
Q Fabry-Pérot microcavity. Distinct lasing emissions from muscle and adipose tissues stained 
respectively with fluorescein isothiocyanate (FITC) and boron-dipyrromethene (BODIPY), and 
hybrid muscle/adipose tissue with dual-staining were achieved with a threshold of only ~10 
J/mm2. It is further found that, despite large fluorescence spectral overlap between FITC and 
BODIPY in tissues, their lasing emissions could be clearly distinguished and controlled due to 
their narrow lasing bands and lasing thresholds, thus enabling highly multiplexed detection.  
 
4.1. Introduction 
4.1.1. Tissue-based lasers  
Biological lasers6 is an emerging field that studies lasing emission from biological and 
biochemical materials such as proteins17-19, vitamins15, luciferins14, DNAs23,33,89,112, and cells17,35-
38,113,  when they are labelled with external fluorophores or they themselves can produce the gain 
media (such as in the case of fluorescent proteins)6,14,35,37,52,114. Advances in biolasers have 
demonstrated great potential in biosensing, biomedical research, and diagnosis17,38,42,52,115,116 due 
to their capability to amplify subtle changes in the gain media caused by underlying biological 
processes, which, in combination of threshold behavior, narrow linewidth, strong lasing emission, 
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and lasing mode spatial distribution, may lead to significant increase in detection sensitivity, 
multiplexibility, and imaging contrast27,30,50,89. Over the past few years, biolasers have been 
focused mainly on the molecular level and cellular level for detecting biomolecules and their 
structural changes9,18,23,32,87,88. Moving beyond the molecular and cellular level, tissues, which 
consist of a collection of cells embedded in extracellular matrix, are generally considered to be 
more practical, since they mimic the actual complex biological environment in a living body. 
Consequently, lasing in tissue (tissue laser) may lead to a broad range of applications in biological 
research, medical diagnosis, and tissue engineering.  
In the past, tissue lasers have been demonstrated in the form of random lasers with a single 
type of fluorophore41,42,116-118, showing capabilities to differentiate and sensitively analyze subtle 
inhomogeneities at the submicron scale116. Additionally, lasing from fat tissues based on 
whispering-gallery modes (WGM) of natural lipid droplets in adipocytes has been succeeded 
lately36. However, random lasers rely on strong scatters (i.e., tissue inhomogeneities) to provide 
optical feedback for lasing and do not have a fixed cavity. Therefore, they are unable to provide 
predicable and trackable laser emission signals with precise locations on the tissue. In addition, 
the lasing characteristics (e.g., intensity and threshold) vary drastically from one tissue sample to 
another or from one spot to another on the same tissue due to the nature of random lasers. WGM 
lasers, on the other hand, require the internal spherical structures of an adipocyte and thus can only 
be used for fat tissues. In both the random laser and the lipid droplet laser, the strong background 
emission from fluorophores and tissues themselves that do not participate in laser action can be 
coupled into the detection system (such as a spectrometer or photodetector) along with the actual 
lasing signal, thus considerably compromising the signal-to-background ratio (SBR) and hence the 
51 
 
detection sensitivity and imaging contrast. Those drawbacks significantly limit practicality and 
applicability of the tissue lasers.  
4.1.2. Multiplexed detection  
Furthermore, detection and differentiation of specific targets (e.g., cancer antibodies) in 
biological tissues have become a critical issue recently119-121. However, the biomedical community 
has come to recognize that no single target analyte is likely to provide sufficient information 
needed to characterize a specific disease in tissues. The ability to detect multiple targets 
simultaneously with a higher sensitivity is therefore highly desirable122. A number of approaches 
have been demonstrated to achieve multiplexed detection and imaging based on fluorescence123, 
photoluminescence124, and Raman spectroscopy125. However, huge spectral emission overlap 
among fluorophores and weak signals (i.e., low SBR) of Raman scattering still restrict their 
applications. In contrast, lasing emission can potentially provide an extremely high SBR and a 
narrow emission band. Unfortunately, the random tissue laser in its current form is unable to detect 
biochemical/biological reactions from specific targets, as the underlying lasing mechanism is 
mainly based on physical properties of tissues (such as inhomogeneities), whereas the lipid droplet 
laser can only react with and detect lipid droplet inside a cell.  
Those challenges motivated us to develop a new versatile tissue laser platform, in which 
tissues stained with various fluorophores are sandwiched in a high-Q Fabry-Pérot (FP) microcavity, 
as illustrated in Fig. 4.1(a). The fluorophores serve as the laser gain medium. Upon external 
excitation, the tissue laser is achieved locally around the focal spot of the pump light. In this 
chapter, we demonstrated for the first time this FP tissue laser. Distinct lasing emissions from 
muscle tissue stained with fluorescein isothiocyanate (FITC), adipose tissue stained with boron-
dipyrromethene (BODIPY), and hybrid muscle/adipose tissue dual-stained with FITC and 
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BODIPY were achieved with a lasing threshold on the order of 10 J/mm2 using the same pumping 
wavelength. We further systematically investigated the lasing characteristics of the tissue laser for 
various tissue structures/geometries, tissue thicknesses, and staining dye concentrations. Finally, 
we achieved lasing from FITC conjugated with phalloidin that target specifically F-actin in muscle 
tissues. 
Our studies reveal the advantages of the FP tissue laser over conventional fluorescence. 
Despite the large fluorescence spectral overlap (~100 nm) between the two fluorophores, FITC 
and BODIPY, lasing bands from muscle and adipose tissues can be clearly distinguished by their 
well separated lasing bands and different lasing threshold, thus enabling highly multiplexed 
spectral detection. In addition, the lasing emission has two orders of magnitude improvement in 
SBR over fluorescence, significantly enhancing imaging contrast. Our tissue laser platform can be 
readily and broadly applicable to nearly any types of tissues/diseases, and outperforms previous 
random tissue lasers and WGM lipid droplet lasers with a low lasing threshold, high sample-to-
sample and location-to-location repeatability, high SBR, multiplexed detection capability, and the 
capability to target specific biomarkers in a tissue. It will open a door to a wide range of 
applications in medical diagnostics and screening of tissues, as well as identification and 
monitoring of biological transformations in tissue engineering. 
 
4.2. Experimental setup 
Optical system setup  
A typical confocal setup was used to excite the sample and collect emission light from the 
FP cavity (Fig. 4.1(a)). In this work, a pulsed OPO laser (pulse width: 5 ns, repetition rate: 20 Hz) 
with 465 nm was used as the excitation source to excite the stained tissues with a laser beam size 
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of 25 μm in diameter. The pump intensity was adjusted by a continuously variable neutral density 
filter, while the lasing emissions were collected through a top CCD and spectrometer. 
 
 
Figure 4.1. Schematic showing the concept of a tissue laser. (a) Illustration of the tissue lasing 
when a tissue is sandwiched within a high-Q Fabry-Pérot (FP) cavity. The thickness of tissue (i.e., 
the cavity spacing) is denoted as d. The typical values for the cavity spacings (d) are around 10-
50μm. During the experiment, the sample was excited by a pulsed optical parametric oscillator 
(OPO) (pulse width=5 ns; wavelength=465 nm). (b) Normalized fluorescence emission spectra of 
FITC in water (blue curve) and BODIPY in ethanol (red curve). c-e, Different types of tissues 
investigated in this work, including muscle tissue (c), adipose tissue (d), and hybrid tissue (e). f, 
Microscopic images of myocytes stained with FITC (from left to right): differential interference 
contrast (DIC) image, confocal microscopy image, and overlap image. (g)Microscope images of 
adipocytes stained with BODIPY (from left to right): DIC image, confocal microscopy image, and  






































Optical imaging techniques  
The differential interference contrast (DIC) and confocal fluorescence microscopic images 
were taken by using Nikon A1 Spectral Confocal Microscope with an excitation of 488 nm laser 
source. The bright field images of tissue lasing were captured by using a CCD (Thorlabs 
#DCU223C ) integrated directly on top of the objective in our laser experimental setup in Fig. 1(a). 
FP cavities 
The FP cavity was formed by two customized dielectric mirrors (Fig. 4.2). The top mirror 
(made by Qingdao NovelBeam Technology Co. Ltd, China) had a high reflectivity in the spectral 
range of 500-555 nm to provide optical feedback and high transmission around 465 nm for the 
pump light to pass through, whereas the bottom mirror (made by Evaporated Coating INC, USA) 
had a slightly wider reflection band. Most part of the top mirror was flat, thus forming a plano-
plano (p-p) FP cavity with the flat bottom mirror. The top mirror also had an array of concave 
structures, made by the computer-controlled CO2 laser ablation (before dielectric coating), thus 
forming a plano-concave (p-c) FP cavity that have better cavity stability and higher Q-factors. The 
Q-factor for the p-p and p-c FP cavity was on the order of 104 and 105, respectively, at a cavity 
length of 30 m (in the absence of tissues). Details of the fabrication and characterization of the 
p-p and p-c FP cavities are described in the reference106.  
 
4.3. Materials and methods 
Tissue and device preparation 
All the fresh pig tissues were obtained from the local slaughterhouse. In this work, the 
muscle and fat tissues were selected from pig ribs without any processing or fixing. Fresh tissues 
were frozen immediately and embedded into OCT (Optimal Cutting Temperature) compound to 
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form an OCT tissue block under -20 oC. Tissue sections were then sliced into thin sections (20 μm, 
30 μm, and 40 μm in thickness) by using a cryostat (Leica 3000). Selected sections were picked 
up and placed on the top of a poly-L–lysine (Sigma-Aldrich #P8920 ) coated dielectric mirror (see 
Fig. 4.2 for details of the mirrors), which were first cleaned and rinsed with Lysine for better tissue 
adhesion. Tissues were then rinsed with PBS (phosphate buffered solution, R&D Systems #841380, 
#896009) and air dried before staining. After staining (see details about staining in the next section) 
and appropriate rinsing again, the tissue was mounted with PBS and covered by the top dielectric 
mirror. For confocal microscopy, the tissues were first deposited on the top of a glass slide 
(Thermo-fisher #3021-002), followed by the same staining process, and then mounted with 
Fluoromount (Sigma-Aldrich #4680) and covered with a coverslip before scanning. 
Staining and materials 
For muscle tissues, FITC powder (Sigma-Aldrich #F6377) was dissolved in de-ionized (DI) 
water at a concentration of 3 mM, then diluted to lower concentrations. FITC solution was then 
applied to the muscle tissue for 10 minutes and rinsed with PBS solution 3 times before 
measurement. For adipose tissues, BODIPY (Life-Tech #D3922) was dissolved in pure ethanol at 
a concentration of 3 mM, then diluted to lower concentrations with ethanol. BODIPY solution was 
then applied to the adipose tissue for 20 minutes and rinsed with PBS solution 3 times before 
measurements. For dual staining of the hybrid tissue, we first applied 2 mM FITC solution to the 
tissue for 10 minutes and rinsed with PBS for 3 times and then 1 mM BODIPY solution for 20 
minutes and rinsed with PBS solution 3 times. For specific staining using FITC-phalloidin 
(Thermo Fisher #F432), the bulk solution was diluted with methanol to form a 10 μM solution and 
applied to the muscle tissue sections for 20 minutes as suggested. Then the tissue was rinsed with 





Figure 4.2. Properties of FP cavity. (a) Schematic of the structure of the FP cavity, showing both 
the plano-plano (p-p) and the plano-concave (p-c) configuration. The concave well array on the 
top mirror was created using CO2 laser ablation before dielectric coating. The two adjacent 
concave wells were 3 mm apart. The rest area on the mirror was flat. (b) The reflectance spectra 
of the top mirror (blue curve) and the bottom mirror (red curve).  
 
4.4. Results and discussion 
4.4.1. Lasing in muscle tissues 
Figure 4.1(a) illustrates the concept of the FP tissue laser. The detailed description of the 
experimental setup is presented in Experimental section. The FP cavity was formed by two 
dielectric mirrors. The details of the mirror fabrication and characterization, as well as FP cavity 
assembly, can be found in Experimental and Fig. 4.2. We used FITC and BODIPY, the two 
commonly used dyes in tissue staining126-128, as the exemplary gain media. Their fluorescence 
















we chose three major types of tissues as the model system, i.e., muscle tissue, adipose tissue, and 
hybrid tissue, as illustrated in Figs. 4.1(c-e). FITC and BODIPY were used to stain muscle tissue 
(myocytes) and adipose tissue (brown adipocytes), respectively. Fig. 4.1(f) shows the DIC and 
confocal fluorescence microscopy images of a muscle tissue stained with FITC. Since FITC is a 
non-specific dye, physical absorption of dyes throughout the whole tissue takes place as the main 
staining mechanism. Nevertheless, it can still be clearly observed that the inner part of each 
myocyte was stained by more FITC due to its slight binding ability to primary amine groups of 
proteins129,130. The DIC and confocal images of adipose tissue stained with BODIPY are given in 
Fig. 4.1(g). Obviously, since BODIPY is a lipophilic stain, it labels all the lipid droplets randomly 
distributed throughout the whole brown adipocyte. 
We first investigated the feasibility and characteristics of the tissue laser under various 
muscle tissue thicknesses and FITC concentrations in Fig. 4.3. All the muscle tissue sections were 
prepared so that muscle fibers (myofibrils) were in the longitudinal direction (i.e., the myofibrils 
were aligned perpendicularly to the mirror surface and in parallel to the laser emission). The lasing 
spectra of a 30 μm thick muscle tissue stained with 2 mM FITC under various pump intensities are 
shown in Fig. 4.3(a). Sharp and periodic lasing peaks start to emerge around 553 nm with an overall 
lasing band of only ~10 nm (545 nm – 555 nm), much narrower than the corresponding 
fluorescence band (>50 nm in Fig. 1b), which is typical for lasing emission25,45,131. The spectral 
linewidth of each lasing peak is 0.2 nm45, limited by the spectrometer resolution. It should be noted 
that, in comparison with the lasing wavelength of pure FITC in the absence of muscle tissue 
(centered around 525 nm – see Fig. 4.4), a 30 nm red-shift in the FITC stained tissue laser was 
observed, which is due to myoglobin in muscle tissue that has a lower extinction coefficient at 555 
nm than 525 nm132. The spectrally integrated laser emission versus pump energy density extracted 
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from Fig. 4.3(a) is presented in Fig. 4.3(b), from which the lasing threshold is derived to be 
approximately 9.2 μJ∕mm2, similar to our theoretical analysis and simulation in the next section. 
 
 
Figure 4.3. Lasing in muscle tissue - longitudinal myofibrils. (a) Examples of lasing spectra of 
muscle tissue (30 μm) stained with FITC (2 mM) under various pump energy densities. Curves are 
vertically shifted for clarity. (b) Spectrally integrated (545 nm – 560 nm) laser output as a function 
of pump energy density extracted from the spectra in a. The solid lines are the linear fit above the 
lasing threshold, which is 9.2 μJ/mm2. (c) CCD images of the muscle tissue laser output below 
(4.7 μJ/mm2) and above (12 μJ/mm2) the lasing threshold. The image shows clearly several 
myocytes. The laser beam was, however, focused on only one of the myocytes. Scale bars, 20 μm. 
(d) Lasing spectra of muscle tissue with different section (cavity) thicknesses (d) at 35 J/mm2 (all 
of which were above the lasing threshold). Curves are vertically shifted for clarity. (e) Laser 
threshold for different tissue thicknesses. The concentration of FITC used to stain the tissue was 
2.0 mM. Error bars were based on three individual measurements at different sites. (f) Laser 
threshold with different concentrations of FITC used to stain the tissue at the fixed tissue thickness 
(and hence the cavity length) of 30 m. The solid curve is a quadratic fit to guide an eye. Error 





Figure 4.4. Lasing spectra of FITC and BODIPY. Laser emission spectra of FITC in water (blue 
curve), BODIPY in ethanol (red curve). Excitation wavelength=465 nm. Pump intensity=35 
μJ/mm2. [FITC]=2.0 mM. [BODIPY]=1.0 mM. Cavity length=30 m. The lasing emission of 
FITC was within the range of 520 nm – 530 nm, whereas the lasing emission of BODIPY was 
within the range of 512 nm – 520 nm. The center of the lasing emission band for FITC is about 10 
nm red-shifted with respect to that of BODIPY due to the slightly red-shift gain profile of FITC 
(see Fig. 1b). Note that the lasing emission band of both FITC and BODIY is much narrower than 
their respective fluorescence band. Consequently, the lasing emission can be distinguished 
between FITC and BODIPY, even though their fluorescence cannot be. 
 
Distinct changes in output emission below and above threshold can be better visualized by 
the CCD images in Fig. 4.3(c). Below the lasing threshold, the emission was spatially featureless 
throughout the focal spot on the tissue. Above the lasing threshold, the laser output is generally 
described by Ince–Gaussian modes133,134. Due to the quasi-circular symmetry of the myofibrils 
inside the cavity, the laser emission in Fig. 4.3(c) looks more like the Laguerre-Gaussian modes. 
We further investigated how tissue thickness and the concentration of staining FITC affect 
the lasing characteristics, which is important for future practical use of tissue lasers in biology and 
biomedicine. Fig. 4.3(d) shows the lasing spectra by varying the muscle tissue thickness with the 
fixed concentration of FITC used to stain the tissue (2 mM). The respective free spectral range 
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(FSR) for the cavity length of 20 μm, 30 μm, and 40 μm is 5.3 nm, 3.5 nm, and 2.7 nm, respectively, 
which give an average effective muscle tissue refractive index of 1.43, close to the reported value 
of 1.41135. Although the number of the lasing modes increases with the increased tissue thickness 
due to the multimode nature of the FP cavity at current lengths (20 m – 40 m), the lasing band 
still remains around 10 nm. Note that the slight increase in background around 560 nm is caused 
by the reduced reflectivity of the dielectric mirror of the FP cavity (Fig. 4.2(b)). Fig. 4.3(e) plots 
the lasing threshold of the tissue laser of various tissue thicknesses, showing the optimal muscle 
tissue thickness is around 30 m. 
Furthermore, we investigated in Fig. 4.3(f) the dependence of the lasing threshold on the 
FITC concentration at the fixed tissue thickness (30 µm). The lasing threshold decreased 
monotonically when the FITC concentration used to stain the tissue increased from 0.25 mM to 2 
mM. The overall agreement between the experimental results with the simulation in section 4.4.2 
suggests that the concentration of FITC inside the muscle tissue follows the concentration of the 
FITC in solution outside the tissue at an approximately 1:1 ratio during staining. This appears to 
be reasonable, as FITC molecules simply migrate into and are subsequently trapped by the tissue 
matrix non-specifically during staining. However, when the FITC concentration exceeds 2 mM, 
the threshold begins to rise again, which is due probably to the self-quenching effect of the dye at 
high concentrations. In fact, the FP laser with pure FITC (in the absence of the muscle tissue) 
shows the similar threshold decrease when the FITC increases from 0.5 mM to 2 mM and the 
similar threshold increase when the FITC concentration increases from 2 mM to 3 mM. Details of 
the lasing spectra and threshold plots of all data points in Figs. 4.3(e) and (f) can be found in Figs. 






Figure 4.5. Lasing spectra of muscle tissue with different cavity length. (a-c) Lasing spectra 
of muscle tissue doped with FITC (2 mM) under various pump energy densities by with the cavity 
length of (a) 20 μm, (b) 30 μm, and (c) 40 μm. All curves are vertically shifted for clarity. (d-f) 
Spectrally integrated (540 nm – 560 nm) laser output as a function of pump energy density 




Figure 4.6. Lasing spectra of muscle tissue with different FITC concentration. (a-d) Lasing 
spectra of muscle tissue doped with FITC (cavity length fixed at 30 μm) under various pump  
energy densities with FITC concentration of (a) 0.25 mM, (b) 0.5 mM, (c) 1.0 mM, and (d) 3.0 
mM. All curves are vertically shifted for clarity. (e-h) Spectrally integrated (540 nm – 560 nm) 
laser output as a function of pump energy density extracted from (a), (b), (c), and (d), respectively. 
Solid lines show the linear fit above the threshold.  
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In order to comprehensively understand how the tissue geometric structures affect the 
lasing properties and thresholds, we compared the lasing from the muscle tissue with the myofibrils 
in the transverse and longitudinal direction (Fig. 4.7(a)). The DIC and confocal fluorescence 
images of transverse myofibrils stained with FITC are given in Fig. 4.7(b). The tissue sections (30 
μm) were cut from the same piece of tissue as in Fig. 4.3 but with different cutting directions and  
 
Figure 4.7. Lasing in muscle tissue - transverse myofibrils. (a) Schematic showing the two 
arrangements of myofibrils (muscle fibers), longitudinal and transverse. Arrows indicate the lasing 
emission direction. The FP cavity is not shown. (b) DIC (upper) and confocal fluorescence 
microscopic (lower) images of transverse myofibrils stained width FITC. (c) CCD images of tissue 
lasing in transverse myofibrils. (d) Examples of lasing spectra of transverse muscle tissue stained 
with FITC under various pump energy densities. Curves are vertically shifted for clarity. (e) 
Spectrally integrated (540 nm – 560 nm) laser output as a function of pump energy density 
extracted from (d). Solid line is the linear fit above the threshold, showing a lasing threshold of 
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sandwiched in the same FP cavity. The lasing characteristics of transverse muscles exhibit a 
remarkable difference from those of longitudinal muscles. First, the spatial pattern of lasing 
emission (Fig. 4.7(c)) resembles linear Hermite-Gaussian modes due to the myofibril arrangement. 
Second, the lasing threshold for the transverse muscle is about 22 μJ/mm2 (Figs. 4.7(d) and (e)), 
approximately 2-3 times larger than for the longitudinal muscle. The lower lasing threshold in the 
longitudinal muscle is due to the light-guiding (light confinement) mechanism along the myofribils 
myofibrils136,137 (see Fig. 4.8 to visualize the light-guiding effect) and fewer interfaces 
(myobribril/sarcolemma) that the light encounters when it travels between the two mirrors.  
 
 
Figure 4.8. Light guiding in myofibrils. Strong light-guiding effect along the myofibrils can be 
clearly observed under a high pump intensity (72 μJ/mm2), which shows that that propagation loss 
is smaller along myofibrils than across myofibrils. Tissue thickness=30 μm. [FITC]=2.0 mM. 




4.4.2. Simulation analysis 
 
Figure 4.9. Simulation of lasing threshold in muscle. (a) Lasing threshold simulation for the 
muscle tissue in the longitudinal direction shows a threshold of ~7 J/mm2. FITC= 2 mM. Cavity 
length=30 m. Tissue extinction coefficient=10 cm-1. (b) Lasing threshold vs. FITC concentration 
inside the muscle tissue. Other parameters are the same as in (a).  
 
The FITC laser is described by: 
ⅆn(𝑡)
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In these equations, n is the concentration of the excited FITC molecules and q is the photon density 
of a lasing mode at FITC emission band. Ip is the photon fluence at the excitation wavelength (465 
nm). 𝜎𝑎,𝑝  is the absorption cross section of FITC at the excitation wavelength. N0 is the total 
concentration of FITC. 𝜎𝑎,𝑙/𝜎𝑒,𝑙  is the absorption/emission cross section of FITC at the lasing 
wavelength. c is the speed of light in vacuum. 𝜀  is the refractive index of the tissue. 𝜏𝑓  is the 
fluorescence lifetimes of FITC. 𝜏𝑞  denotes the lifetime of the photon in the lasing mode and is 
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 results from the loss of mirrors (Q0, empty cavity 
quality factor; 𝜆, lasing wavelength) and  𝜏𝑠 =
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presence of tissue (𝛼 , tissue extinction coefficient). With the round trip loss limited by the 
transmission of the bottom mirror (0.5%), Q0 of an FP cavity with a cavity length of 30 m is 
1.9e5. The extinction coefficient of tissue, α = 𝛼𝑠 + 𝛼𝑎, where 𝛼𝑠 is scattering loss and 𝛼𝑎 is the 
absorption of myoglobin. Here we only consider the forward scattering since the thickness of the 
muscle tissue is far less than 1mm. Therefore we can simply use the reduced scattering coefficient 
of muscle in longitudinal orientation for simulation (scattering loss approximately is 9 cm-1 138,139). 
The myoglobin absorption coefficient is 1 cm-1. V is the mode volume and F is the fraction of the 
mode volume occupied by the tissue. To simulate the pulse excitation condition, we assume the 
excitation photon fluence Ip to be Gaussian with a full width at half maximum (FWHM) of 5 ns. 
Pump intensity is determined by temporal integral of Ip from time zero to infinity. The coupled rate 
equations are numerically solved in Matlab for different conditions. Output intensity is determined 
by temporal integral of q(t) assuming a constant out-coupled rate. Parameters used in the 
simulation are summarized in Table 1 below. 
 
Table 1. Simulation parameters 
Symbols Description Numeric values 
𝜎𝑎,𝑝 Absorption cross section at excitation wavelength 1.25e-16 cm2 
𝜎𝑎,𝑙  Absorption cross section at lasing wavelength <1e-19 cm2 
𝜎𝑒,𝑙 Emission cross section at lasing wavelength 1.19e-16 cm
2 
c Speed of light in vacuum 30 cm/ns 
𝜀 Refractive index of tissue 1.40 
𝜏𝑓 Fluorescence lifetime of FITC 4.1 ns 
V Volume of the electromagnetic mode 2.7e-8 cm3 
F Fraction of mode volume occupied by the dye molecules 1 
Q0 Empty cavity quality factor (cavity length=30 m) 1.9e5 
 Lasing wavelength 550 nm 
α Tissue extinction coefficient 𝛼𝑠 + 𝛼𝑎 
𝛼𝑠 Tissue scattering loss Longitudinal, 9 cm
-1 





4.4.3. Lasing in adipose tissues 
To demonstrate the versatility of our tissue laser platform, in Fig. 4.10 we further studied 
the lasing properties of brown adipose tissue stained with BODIPY. The lasing spectra of a 30 μm 
brown adipose tissue stained with 1 mM BODIPY under various pump energy densities is shown 
in Fig. 4.10(a). Periodic lasing peaks start to emerge around 528 nm and the overall lasing band is 
approximately 15 nm (520 nm - 535 nm), still much narrower than the corresponding fluorescence 
band. Due to the absence of myoglobin the lasing band of the adipose tissue is red-shifted only 10 
nm with respect to that from pure BODIPY lasing (see Fig. 4.4), much smaller than the 30 nm red-
shift observed for the muscle laser discussed previously. The spectrally integrated laser emission 
versus pump energy density presented in Fig. 4.10(b) shows the lasing threshold of approximately 
20 μJ∕mm2. Prominent changes in output emission below and above threshold were obtained 
through the CCD images in Fig. 4.10(c). Below the lasing threshold (15 μJ∕mm2), the emissions 
was spatially featureless throughout the focal spot on the tissue. Above the lasing threshold (31 
μJ∕mm2), the spatial output exhibits more irregular patterns than that for the muscle tissues 
arranged longitudinally or transversely, because of various sizes of lipid droplets randomly 
distributed within the focal point of the pump light. 
The effect of tissue thickness and BODIPY concentration on the lasing characteristics were 
also studied. Fig. 4.10(d) shows the lasing spectra of various tissue thicknesses with the fixed 
BODIPY concentration at 1 mM. The measured FSR for the cavity length of 20 μm, 30 μm, and 
40 μm is 4.5 nm, 2.9 nm, and 2.2 nm, respectively, which result in an average effective tissue 
refractive index of 1.55, close to the reported value of 1.48135,140. The lasing threshold for various 
tissue thicknesses is shown in Fig. 4.10(e), showing the optimal tissue thickness of about 30 m, 
similar to that for the muscle tissue. Fig. 4.10(f) shows the dependence of the lasing threshold on 
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the BODIPY concentration at a fixed adipose tissue thickness. The lasing threshold decreased 
gradually between 0.5 mM to 2 mM. However, due to the self-quenching effect of BODIPY, the 
lasing threshold rises when the concentration exceeds 2 mM, which is also similar to what we 
observed for the muscle tissue with FITC. Details of the lasing spectra and threshold plots of all 




Figure 4.10. Lasing in adipose tissue. (a) Examples of lasing spectra of adipose tissue (30 μm) 
stained with BODIPY (1.0 mM) under various pump energy densities. Curves are vertically shifted 
for clarity. (b) Spectrally integrated (520 nm – 535 nm) laser output as a function of pump energy 
density extracted from the spectra in a. The solid lines are the linear fit above the lasing threshold, 
which is approximately 20.0 μJ/mm2. (c) CCD images of the muscle tissue laser output below (15 
μJ/mm2) and above (31 μJ/mm2) the lasing threshold. The image shows clear boundaries of several 
adipocytes, in which the laser beam is focused on only one of the fat cells. Scale bars, 20 μm.  (d) 
Lasing spectra of adipose tissues of different thicknesses above the lasing threshold. (e) Laser 
threshold for different tissue thicknesses. The concentration of BODIPY used to stain the tissue 
was 1.0 mM. Error bars were based on three individual measurements at different sites. (f) Laser 
threshold with different concentrations of BODIPY used to stain the tissue at the fixed tissue 
thickness (and hence the cavity length) of 30 m. The solid curve is a quadratic fit to guide an eye. 





Figure 4.11. Lasing spectra of adipose tissue with different cavity length. (a-c) Lasing spectra 
of adipose tissue doped with BODIPY (1.0 mM) under various pump energy densities with the 
cavity length of (a) 20 μm, (b) 30 μm, and (c) 40 μm. All curves are vertically shifted for clarity. 
(d-f) Spectrally integrated (515 nm – 535 nm) laser output as a function of pump energy density 
extracted from (a), (b), and (c), respectively. Solid lines show the linear fit above the threshold.  
 
Figure 4.12. Lasing spectra of adipose tissue with different BODIPY concentration. (a-d) 
Lasing spectra of adipose tissue doped with BODIPY (cavity fixed at 30 μm) under various pump 
energy densities with BODIPY concentration of (a) 0.5 mM, (b) 1.0 mM, (c) 2.0 mM, and (d) 3.0 
mM. All curves are vertically shifted for clarity. (e-h) Spectrally integrated (515 nm – 535 nm) 
laser output as a function of pump energy density extracted from (a), (b), (c), and (d), respectively. 
Solid lines show the linear fit above the threshold.  
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4.4.4. Multiplexed lasing in tissues 
After studying individual dyes with individual types of tissues, we further achieved 
selective and multiplexed lasing from a hybrid tissue (Fig. 4.13(a)), which allows us to generate 
lasing signals from myocytes and adipocytes on the same piece of tissue. The tissue was dual-
stained, i.e., FITC was used to bind mostly proteins (myocytes) and BODIPY to lipids (adipocytes). 
DIC and confocal microscopic images were used to confirm the dual staining process in tissue 
(Figs. 4.13(b) and (c)). By tuning the pump light focal position, we were able to achieve lasing 
emission by scanning along the tissue in one direction, as shown in the dotted lines in Figs. 4.13(b) 
and (c). Here we chose 3 sites to represent two different tissues: site 1 (muscle tissue with 2 mM 
FITC), site 2 (adipose tissue with 1 mM BODIPY), and site 3 (muscle tissue with 2 mM FITC). 
Fig. 4.13(d) shows the conventional fluorescence spectra measured at site 1, 2, and 3 (in the 
absence of the FP cavity by removing the top mirror). Apparently, we would not be able to 
distinguish the tissue type among these three sites by their fluorescence, thanks to the huge spectral 
overlap between FITC and BODIPY. In contrast, by placing the same tissue in the FP cavity (by 
putting the top mirror back), lasing signals (and hence the tissue type) of these three sites can be 
distinguished in Figs. 4.13(e) and (f). Fig. 4.13(e) shows the selective lasing emission from only 
one type of tissue (and dye). In this case, the pump energy density (20 μJ/mm2) was set between 
the threshold for FITC and BODIPY. Only lasing signals from FITC (site 1 and site 3) were 
generated. No laser signals could be detected from BODIPY (site 2). Since the mirror blocks 
significant amount of fluorescence background and allows only the laser emission to pass, an 
extremely high contrast ratio (~103) between site 1 and 2 can be achieved. For comparison, the 
contrast of fluorescence between site 1 and site 2 is nearly unity (see Fig. 4.13(d)). Fig. 4.13(f) 
demonstrates the multiplexed lasing emission from multiple dyes. In this case, a higher pump 
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energy density (60 μJ/mm2) was used to obtain the lasing emission from both FITC and BODIPY. 
Despite strong spectral overlap in fluorescence, the lasing spectra from FITC and BODIPY are 
vastly different spectrally, thus allowing for clear differentiation between muscular and adipose 
 
Figure 4.13. Multiplexed lasing in hybrid tissue. (a) A photo of the piece of hybrid tissue used 
in this experiment. The labeled black squared is the region of interest where muscle tissues and 
adipose tissues are unable to distinguish directly by its appearance.  (b) DIC image of the hybrid 
tissue labeled in (a) containing an irregular mixture of adipose tissues and muscle tissues. Three 
representative sites were taken on (site 1) muscle tissue, (site 2) adipose tissue, and (site 3) muscle 
tissue, respectively, as the pump laser beam scanned through one direction (see the dashed arrows). 
(c) Confocal image of the hybrid tissue dual-stained with FITC and BODIPY. (d) Fluorescence 
spectra of muscle tissue with FITC (site 1), adipose tissue with BODIPY (site 2), and muscle tissue 
with FITC (site 3). (e) Lasing spectra taken at site 1, 2, and 3, respectively, when the pump energy 
density was set between the threshold for muscle tissue and for adipose tissue (20 μJ/mm2). (f) 
Lasing spectra taken at site 1, 2, and 3, respectively, when the pump energy density was above the 
threshold for both muscle tissue and adipose tissue (60 μJ/mm2). Note that the increase in the 
background emission spectra around 560 nm in (e) and (f) is due to the fluorescence leaking out 
of the FP cavity caused by the reduced reflectivity of the dielectric mirror. Scale bars in (b) and 






















































































































Figure 4.14. Signal to background ratio of fluorescence and laser emission in tissue. 
Comparison of the signal to background ratio (SBR) between fluorescence and lasing emission. 
(a) Fluorescence spectrum of adipose tissue stained with BODIPY (red) and its background (blue). 
(b) Lasing spectrum of adipose tissue stained with BODIPY and its background (blue). (c) SBR 
extracted from (a) showing the maximal value of about 10. (d) SBR extracted from (b) showing 
the maximal value of about 500. All the background signals were measured using the tissue sites 
without staining under the same configuration. [BODIPY]=1.0 mM. Pump energy density=60 
μJ/mm2. Excitation wavelength=465 nm. Fluorescence was measured by removing the top mirror. 
 
 
tissues. The above two examples attest to the ability of the tissue laser to control and distinguish 
lasing signals in the presence of multiple dyes. Such ability arises from the sensitive dependence 
of the laser characteristics (such as lasing wavelength and threshold, as well as output intensity 
and polarization) on the emission/absorption properties of dyes and their biochemical and physical 
environment (such as tissue scattering/absorption and binding affinity of dyes to particular markers 
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on tissue, etc.), which enables highly multiplexed analysis of tissues using various fluorophores. 
In addition to spectrally resolving two very similar dyes, the tissue laser provides another benefit, 
i.e., high SBR. As exemplified in Fig. 4.14, the SBR in the tissue laser is 500, about 50-fold 
improvement over conventional fluorescence based detection. Note that since the random laser 
does not have a mirror41,42,116-118, strong fluorescence or scattering background will still be detected 
without being blocked, thus significantly reducing the SBR.  
 
4.4.5. Lasing with specific conjugates and mirrors  
In many applications, fluorophores are conjugated to biochemical molecules in order to 
specifically bind to the target in a tissue. To demonstrate that the tissue lasing technique can be 
applied to fluorophore-conjugates, in Fig. 4.15 we employed FITC-phalloidin as a model system, 
which has high affinity for F-actin in muscle tissues141. In this experiment, lasing could be achieved 
by using only 10 M FITC-phalliodin to stain the muscle tissue (Fig. 4.15(a)). In comparison with 
non-specific binding of FITC (Fig. 4.1(f)), the specific binding of FITC-phalloidin to F-actin 
resulted in localized fluorescence near cell membranes under confocal microscopy (Fig. 4.15(c)) 
and made the FITC concentration in the muscle tissue much higher than the original staining FITC-
phalloidin concentration (10 M). Consequently, lasing from FITC could be achieved with a 
threshold about 130 J/mm2 (Fig. 4.15(b)), while no lasing was observed with non-specific FITC 
in muscle tissue even at 300 J/mm2 under the same conditions and using the same staining FITC 
concentration (10 M). Based on our simulation in Fig. 4.9(b), the effective FITC-phalloidin 
concentration inside the tissue is estimated to be ~200 M. In Fig. 4.15(d), the spatial distribution 




Figure 4.15. Lasing in muscle tissue with FITC conjugates. (a) Examples of lasing spectra of 
the muscle tissue stained with FITC-phalloidin under various pump energy densities. The lasing 
is centered around 535 nm. This blue shift with respect to the lasing emission around 550 nm for 
1 mM FITC is typical for a laser when the gain medium concentration decreases52,67. (b) Spectrally 
integrated (530 nm – 545 nm) laser output as a function of pump energy density extracted from 
(a). Solid line is the linear fit above the threshold, which is approximately 130 μJ/mm2.  (c) 
Confocal fluorescence image of the muscle tissue stained with FITC-phalloidin. The muscle was 
arranged longitudinally. (d) CCD images of lasing emission above the lasing threshold. All scale 
bars, 20 μm. Tissue thickness=30 μm. [FITC-phalloidin]=10 μM. Excitation wavelength=465 nm.  
 
In all the experiments presented so far, we used the plano-plano (p-p) FP cavity, which is 
well known to be unstable and susceptible to Q-factor degradation even with slight 
misalignment106,142, and might also have contributed to the variations in the lasing threshold for 
different tissue thicknesses in Fig. 4.3(e). Such Q-factor degradation is less significant in the case 
of single-cell lasers due to the lensing effect of the cell37. Unfortunately, this lensing effect may 
not exist for tissue lasers when cells are embedded in the extracellular matrix. In contrast, plano-
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concave (p-c) FP cavities are highly stable and the high Q-factor can be maintained even with 
misalignment during assembly of the FP tissue laser. As a proof of concept, we created an array 
of micron-sized concave mirrors (3 mm apart between two adjacent concave mirrors) using CO2 
laser ablation on the same top mirror106 (see Fig. 4.2) and tested with the same FITC stained muscle 
tissue. The Q-factor of those p-c FP cavities exceeded 105, according to our previous work106. As 
shown in Fig. 4.16, a lasing threshold of approximately 2 J/mm2 was achieved, ~10 times lower 
than the corresponding p-p FP cavity in Fig. 4.3 and about 100 times lower than the random tissue 
laser (90-380 J/mm2)41,42,115. Currently, our top mirror design does not allow us to scan the 
concave mirror. In the future, a high-Q scanning concave mirror can be created on the tip of an 
optical fiber143,144 to examine the entire tissue. 
 
 
Figure 4.16. Lasing in tissue with concave FP cavity. (a) Examples of lasing spectra of muscle 
tissue stained with FITC using a concave top mirror under various pump energy densities. (b) 
Spectrally integrated (540 nm – 560 nm) laser output as a function of pump energy density 
extracted from (a). Solid line is the linear fit above the threshold, showing a lasing threshold of 








4.5. Conclusion  
In this work, we have studied and developed a highly versatile tissue laser platform based 
on a high-Q FP cavity. Although only two dyes and two types of tissues were demonstrated in the 
current studies, there is no doubt that the tissue laser platform can readily be translated to other 
fluorophores (such as quantum dots145 and fluorescent proteins) and other types of tissues. Such a 
tissue laser offers narrow spectral bandwidth, strong emission intensity, and large background 
rejection, which, coupled with the positive feedback provided by the laser cavity, can significantly 
improve the sensitivity, specificity, multiplexibility, and imaging contrast in tissue 
characterization. Besides emission intensity, the laser output from tissues consist of a number of 
unconventional parameters that can be monitored and serve as the sensing signal, such as lasing 
threshold, lasing efficiency, and lasing mode spatial distribution. Collectively, the multi-parameter 
analysis would enable better understanding of intratissue/intertissue biological activities and 
structures.  
In the near future, a few research directions will be explored towards eventual practical use 
of the tissue laser. First, integration with an imaging spectrometer will be implemented for 
advanced tissue mapping with higher spectral and spatial information.  Secondly, fluorophores 
conjugated with antibodies can be used to target multiple biomarkers in tissues. We envision that 
our tissue laser will provide a novel spectroscopic tool for a plethora of applications ranging from 
medical diagnostics and preclinical drug testing to monitoring and identification of biological 








Mapping Nuclear Biomarkers with Laser Emissions for Cancer 
Diagnostics 
Based on the development of “versatile tissue lasers” in Chapter 4, here in Chapter 5 we aim to 
translate such concept into clinical applications. Besides lasing with common non-site-specific 
dyes, the ability to detect biomarkers with lasing method will be particularly significant. In 
particular, nuclear biomarkers such as nucleic acids and nuclear proteins is critical for early-stage 
cancer diagnosis and prognosis. Conventional methods relying on morphological assessment of 
cell nuclei in histopathology slides may be subjective, whereas colorimetric immunohistochemical 
and fluorescence-based imaging are limited by strong light absorption, broad-emission bands and 
low contrast. Here, we describe the development and use of a scanning laser-emission-based 
microscope that maps lasing emissions from nuclear biomarkers in human tissues. 41 tissue 
samples from 35 patients labelled with site-specific and biomarker-specific antibody-conjugated 
dyes were sandwiched in a Fabry-Pérot microcavity while an excitation laser beam built a laser-
emission image. We observed multiple sub-cellular lasing emissions from cancer cell nuclei, with 
a threshold of tens of μJ/mm2, sub-micron resolution, and a lasing band in the few-nanometre range. 
Different lasing thresholds of nuclei in cancer and normal tissues enabled the identification and 
multiplexed detection of nuclear proteomic biomarkers, with a high sensitivity for early-stage 





Nucleus lies in the heart of every cell and carries abundance of nuclear proteins and the 
majority of cell’s genetic materials. Molecular changes in the levels of nucleic acids and chromatin 
and altered expression patterns of nuclear-matrix proteins are highly relevant to malignant 
progression146. Recent studies have found that a higher level of nucleic acids (aggregates of 
chromatins) are present in various cancers146-149, indicating the potential use of nucleic acids for 
cancer screening and monitoring. In addition, overexpression of specific protein biomarkers, such 
as epidermal growth factor receptor (EGFR)150-152, cellular tumor antigen p53153, cell regulator 
protein Bcl-2154, and cell division cycle protein CDK-1155, in cell nuclei, is of particular prognostic 
significance156, as they are highly correlated with patients’ survival rate and their response to 
chemotherapy and radiotherapy in many types of cancers (e.g., lung cancer151, triple-negative 
breast cancer157, colorectal cancer158, ameloblastoma159, ovarian cancer160, gastric cancer and 
colorectal cancers154,161). Detection and evaluation of those nuclear biomarkers (nucleic acids, 
genetics, and proteins) in human tissues will not only help scientists better understand the signaling 
pathway in cancers, but more importantly, provide critical information for early stage cancer 
diagnosis, prognosis, malignant transformation, and the efficacy of anticancer therapies124,162-165.  
To date, evaluation of microscopic histopathology slides by pathologists still remains as 
the golden standard for cancer diagnosis, which is based mainly on the morphological assessment 
of cell nuclei in tissues using the Hematoxylin and Eosin (H&E) staining166,167. However, due to 
the lack of quantitative analysis capability, this method is highly subjective and even the best -
characterized histopathological features receive only modest agreement among experienced 
pathologists, which may result in misdiagnosis and poor treatment management168. This issue 
becomes particularly serious and challenging when we deal with very early stage cancers169. 
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Meanwhile, for cancer prognosis and guided therapy, immunohistochemistry (IHC) is 
widely used to analyze specific antigens, especially those prognostic and predicative 
biomarkers170,171. IHC relies on colorimetric detection to identify the location of a given proteomic 
biomarker within a tissue. While simple, IHC performs poorly in distinguishing biomarkers in 
nuclei from their surrounding background due to the nonlinear optical effect and low dynamic 
range165 (example given in Fig. 5.1). Consequently, the cells having overexpressed nuclear 
proteomic biomarkers may be misdiagnosed. This problem exacerbates when multiple targets in a 
nucleus are to be analyzed. Compared to colorimetric detection, immunofluorescence (IF) uses 
different fluorescent labels to tag different biomarkers, thus resulting in improved contrast and 
multiplexing capability over IHC123,124. However, despite elevated biomarker concentrations in the 
nuclei for the cancers at an advanced stage, the fluorescence signals from the nuclear biomarkers 
are oftentimes embedded in a large patch of background fluorescence from cytoplasm that may 
also have the expression of the same biomarkers (Fig. 5.1). In addition, IF suffers significantly 
from the broad emission spectra of fluorophores, which poses yet another hurdle to distinguish the 
biomarkers from nearby features with similar emission wavelengths. Therefore, it becomes 
challenging to accurately identify the nuclei having biomarker expression and further precisely 
pinpoint the exact biomarker locations inside the nuclei, which may cause significant distortion in 
and subsequent misinterpretation of the cancer tissue characterization172.  
In comparison with fluorescence-based detection, laser emission has narrow linewidth, 
threshold behavior, high intensity, and high sensitivity to biomolecular/cellular changes 6,15,27,30,35-
39,52,87,113,115,173,174. Therefore, biolasers may provide a new bioanalytical tool that complements 
traditional fluorescence techniques. In one of the biolaser embodiments, bio-species (such as 
biomolecules, cells, and tissues) are placed inside a Fabry-Pérot (FP) cavity and the laser 
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characteristics such as lasing wavelength, threshold and intensity are modulated passively (i.e., 
bio-species are not labeled and the gain media are outside those bio-species)38,39,173 or actively (i.e.,  
bio-species are labeled with fluorophores that serve as the laser gain media)29,35,114. However, to 
date, no studies have been carried out to use biolasers to identify and detect specific biomarkers 
within cells/tissues, in particular, using actual patients’ samples. Whether biolasers can truly 
provide new bioanalytical capability remains a question that has yet to answer. 
 
Figure 5.1. IHC and IF images of nuclear EGFR. (a) IHC images of human lung 
adenocarcinoma tissues having different levels of n-EGFR expression. (i) Tissue without n-EGFR; 
(ii) Tissue with moderate n-EGFR expression; (iii) Tissue with severe n-EGFR expression. Both 
the cells with n-EGFR in (ii) and (iii) appear darkish and thus becomes difficult to distinguish 
between the EGFR expression within the nuclei and in the cytoplasm. (b) Confocal 
immunofluorescence (IF) microscopic images of human lung adenocarcinoma tissues with (right 
image) and without (left image) n-EGFR expression. In the right image, although the contrast 
against EGFR in the surrounding cytoplasm is enhanced, the details inside each nucleus still cannot 
be well characterized. All tissues were first stained with anti-human EGFR antibody, followed by 
HRP-conjugated anti-Rb IgG antibody with DAB substrate for (a) and FITC-conjugated anti-Rb 





Figure 5.2. Conceptual illustration of the laser-emission based microscope.  (a) Illustration of 
the laser-emission based microscope (LEM) configuration when a human cancer tissue is 
sandwiched within a high-Q Fabry-Pérot cavity and integrated with a 2D raster scanning stage. 
The laser emission from fluorophores is achieved upon external excitation. The inset shows the 
details of using nucleic acid staining dyes and antibody-conjugated dyes to achieve multiplexed 
laser emissions from a tissue. Laser emissions are achieved only when probes are bound to the 
nucleus or targeted nuclear biomarker within the tissue.  Here only one antibody is plotted for 
example; however, multiple targeted antibodies/fluorophores can be used. (b) Comparison 
between the traditional fluorescence emission (top) and “star-like” laser emission (bottom) from a 
single nucleus. (c) (Left) Output intensity of laser emission as a function of pump intensity. Pc, 
lasing threshold of cancer cell lasing; Pn, lasing threshold of normal cell lasing. A higher/lower 
nucleic acid concentration leads to a lower/higher lasing threshold. (Right) Laser emission (red 
solid line) has a much narrower emission profile than traditional fluorescence (blue dashed line) 
(d) Fluorescence emission is detected in both normal and cancer cell nuclei, whereas laser emission 






In this chapter we proposed a scanning “laser-emission-based microscope” (LEM) for 
improved tumor tissue characterization based on the earlier devolvement of the tissue laser 
platform29. Successful mapping of the lasing emissions from nuclear biomarkers (such as nucleic 
acids and/or specific antigens) were achieved in human tissues with a sub-cellular and sub-micron 
resolution (<700 nm) and a lasing threshold on the order of tens of J/mm2. Fig. 5.2(a) illustrates 
the concept of the LEM, in which a tissue labeled with site specific fluorophores (e.g., nucleic acid 
probes) and/or antibody-conjugated fluorophores is sandwiched inside an FP microcavity formed 
by two mirrors. The fluorophores serve as the laser gain medium, which are designed to respond 
to intracellular binding and intratissue activities, thus generating the sensing signal in the form of  
laser emission. A 2D scanning stage was integrated to map the tissue and construct images by 
scanning the pump beam across the whole tissue. As illustrated in Fig. 5.2(b), while fluorescence 
(top illustration) from a nucleus usually provides “spatially-blurred” signal, which covers a large 
area with a low spatial resolution and a low contrast between the sites with high and low biomarker 
expressions, laser emission (bottom illustration) offers distinct advantages due to its high 
intensity/sensitivity6,27,36,113, high fluorescence background suppression (for high contrast 
imaging)29,30, high spatial resolution6,28, high spectral resolution (for highly multiplexed detection), 
and unique threshold behavior (to selectively switch on/off specific laser emission signals (Figs. 
5.2(c) and 5.2(d))18. 
In particular, lasing with lung and colon cancer tissues was demonstrated with a total of 41 
samples from 35 patients’ biopsies (N=41 and >100 tissue sections) involved. Nucleic acid dye, 
YO-PRO-1 Iodide (YOPRO), and several antibodies (e.g., anti-EGFR, mutant-p53, and Bcl-2) 
conjugated with fluorescein isothiocyanate (FITC) were used to analyze nucleic acids and the 
proteomic biomarkers within the nuclei, respectively. We demonstrated that the LEM is able to 
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not only clearly distinguish between cancer and normal tissues, but diagnose early stage lung 
cancer tissues with a high sensitivity of 97.5%. Tumor tissues with and without nuclear proteomic 
biomarkers can be quantified due to vastly different lasing thresholds resulting from different 
nuclear expressions of biomarkers. Furthermore, we showed the wavelength-multiplexed immuno-
lasing capability of the LEM. Dual lasing emissions were achieved to signify the co-localization 
of nucleic acid and nuclear proteomic biomarkers. We envision that this study will provide an 
imaging tool complementary to H&E, IHC and IF for better cancer diagnosis and prognosis, as 
well as to improve the basic understanding of fundamental cell biology. 
5.2. Experimental setup of laser-emission microscope 
Fabry-Pérot microcavity  
The FP microcavity was formed by two customized dielectric mirrors (Fig. 5.3). The top 
mirror (made by Qingdao Novel Beam Technology Co. Ltd, China) had a high reflectivity in the 
spectral range of 520 nm - 555 nm to provide optical feedback and high transmission around 465 
nm for the pump light to pass through, whereas the bottom mirror (made by Evaporated Coating 
INC, USA) had a slightly wider reflection band. The respective reflectivity for the top mirror and 
bottom mirror at the lasing wavelength (535-555 nm) is approximately 99.8% and 99.9%, while 
the transmission of the top mirror at pump wavelength (465 nm) is ~ 90.2%. The Q-factor for the 
FP cavity was on the order of 104, at a cavity length of 15 m (without tissues). Details of the 
fabrication and characterization of the FP cavities are described in the reference8. 
Laser emission microscope (LEM) system  
The bright field IHC images were taken with a Nikon-E800 Wide field Microscope. The 
confocal fluorescence microscopic images were taken by using a Nikon A1 Spectral IF Confocal 
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Microscope with an excitation of 488 nm laser source. The bright field images of the laser 
emissions (“lasing stars”) in tissues were captured by using a CCD (Thorlabs #DCU223C) 
integrated directly on top of the objective in our experimental setup (see Fig. 5.3(a)). 
 
 
Figure 5.3. LEM setup and mirror profile. (a) Schematic of the experimental setup of the laser-
emission based microscope (LEM) and structure of the FP cavity. The focal beam size (spatial 
sampling area of the spectrum) is 30 µm in diameter. The enlarged figure on the right shows the 
picture of a lung tissue section sandwiched between the two mirrors while pumped by a 465 nm 
excitation source. (b) The reflectance spectra of the top mirror (purple curve) and the bottom mirror 
(red curve). The reflectivity of the mirrors around the lasing emission wavelength (535-555 nm) 




A typical confocal setup was used to excite the sample and collect emission light from the 
FP cavity (see the optical setup in Fig. 5.3(a)). A pulsed OPO laser (pulse width: 5 ns, repetition 
rate: 20 Hz) at 465 nm was used to excite the stained tissues. The FWHM of the focused laser 
beam size was ~ 30 μm in diameter, in which the spatial sampling area is slightly larger than the 
focal beam size. The emission light was collected through the same objective then separated by a 
beam splitter to the spectrometer and CCD for spectral and image analysis.  
The laser-emission scanned images were collected through the same optical setup, in which 
the images were taken by the CCD (10 fps, Thorlabs #DCU223C) mounted on top of the objective 
(NA 0.42, 20X). The raster scanning stage was home-built using two linear actuators with electric 
controllers (Newport #CONEX TRA25CC) and integrated with a raspberry PI/ touchscreen 
(Digikey #8997466) for operation. The LEM images shown in Figs. 5.12-5.15 (FOV of 150 μm x 
150 μm per frame in this work) was formed by mapping and integration of 25 individual CCD 
images (30 μm x 30 μm). However, larger mapping area up to 1mm x 1mm is achievable with the 
aid of algorithms. Currently the accuracy of the stage is limited by 3 μm during each displacement. 
 
5.3. Materials and methods 
Tissue materials and device preparation 
In this study, a total of 41 tissue samples (N=41) from 35 patients’ tissue were used, 
including human lung tissues (N=38, labeled as P1-P32) and human colon tissues (N=3, P33-P35). 
In particular, P18-P20 are identified as early stage lung cancer samples. All the human lung and 
colon tissues were purchased from OriGene Technologies in the form of OCT (Optimal Cutting 
Temperature) frozen tissue blocks. Both male and female patients diagnosed with stage I/II cancer, 
aging from 46-78 were examined. All human subjects are fully informed and are explicitly asked 
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for their consent to future research use of their samples. Samples are collected from a diverse set 
of medical institutions throughout the United States in order to maximize patient diversity. Those 
tissues were verified at the Company by pathologists with full pathological evaluation data, clinical 
annotation (including patient age, gender, and minimum stage grouping), abstracted pathology 
reports to ensure the accuracy of the sample level diagnosis (i.e., a normal adjacent sample 
collected from a cancer patient) and detail the sample’s cellularity (% normal cells, % lesion cells, 
% tumor cells, % stroma and % necrosis). For the exemplary tissues demonstrated used in Fig. 8, 
both tissues were examined by  pathologists and verified with lung adenocarcinoma and EGFR. 
Upon receiving, all OCT tissue blocks were sliced into 15 μm thick sections by using a 
cryostat (Leica 3050S). The selected tissue section was picked up and placed on the top of a poly-
L–lysine (Sigma-Aldrich #P8920) coated dielectric mirror, which was first cleaned and rinsed with 
lysine for better tissue adhesion. The tissue were then rinsed with PBS (phosphate buffered 
solution, ThermoFisher # 10010023) and air dried before staining/labeling (see staining/labeling 
details in the next section). Finally, the tissue was covered by the top dielectric mirror. For confocal 
IF microscopy, the tissue was first deposited on the top of a superfrost glass slide (ThermoFisher 
#3021-002), followed by the same staining process, and then mounted with Fluoromount (Sigma-
Aldrich #4680) and covered with a coverslip before scanning. 
For the optical laser experiments, all tissues were first examined with H&E histopathology 
slides to select the area that consists of all tumor cells or all normal cells. All of the tissues were 
sectioned into 4 slices and at least 5 cells within the tumor/normal region from each tissue section 
were randomly selected and measured. All cells were measured under various pump energy density 




Staining and labeling methods 
For IHC staining, the tissue was fixed on a superfrost glass slide (ThermoScientific #15-
188-48) by immersing in pre-cooled acetone (-20 °C) for 3 minutes and dried off at room 
temperature. The slide was then rinsed with PBS twice. Next, the tissue was first blocked with 
BSA buffer for 10 minutes to prevent non-specific binding and rinsed with PBS thoroughly. Then 
the tissue was incubated with 200 µl of diluted primary antibody (anti-human-EGFR antibody 
(abcam #52894) overnight at 4 oC. The primary antibody was prepared with 1:50 solution, with a 
final concentration of 0.005 mg/ml. After incubation of primary antibodies, the tissue was rinsed 
with PBS, followed by 30 minutes of staining with HRP conjugated anti-Rb IgG secondary 
antibody (abcam #6721) at room temperature with a dilution of 1:200 (final concentration=0.01 
mg/ml). Then DAB substrate solution (abcam #64238) was applied to the tissue for 5 minutes to 
reveal the color of the antibody staining. After rinsing 5 times, the tissue was dehydrated through 
pure alcohol, then mounted with mounting medium (abcam #ab64230), and finally covered with a 
coverslip. The same procedure was applied to both lung and colon tissues. For colon tissues, two 
additional primary antibodies, anti-mutant p53 (abcam #32049) and anti-Bcl-2 (abcam #182858), 
were used. 
For nucleic acid labeling, YOPRO solution (ThermoFisher #Y3603) was dissolved in PBS 
at a concentration of 0.5 mM, then diluted to lower concentrations with PBS. The prepared 
YOPRO solution was then applied to the tissue sections for 10 minutes and rinsed with PBS 
solution three times before measurements. The above process is the same for both IF and laser 
measurements.  
For antibody-fluorophore labeling of lung tissues, the glass slide was first rinsed with PBS 
twice and blocked with BSA buffer for 10 minutes to prevent non-specific binding, then rinsed 
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again with PBS. Next, the tissue was incubated with 200 µl of diluted primary antibody (anti-
human-EGFR antibody (abcam #52894)) overnight at 4 oC. The primary antibody was prepared 
with 1:50 solution, with a final concentration at 0.01 mg/ml. After incubation with primary 
antibodies, the tissue was rinsed with PBS thoroughly, followed by FITC conjugated anti-Rb IgG 
secondary antibody (stained for 2 hours at room temperature). The secondary antibody 
(ThermoFisher #65-6111) was prepared with 1:5 dilution to reach the final concentration of 0.2 
mg/ml. Finally, the tissue was rinsed again with PBS before laser experiment. The same procedure 
was applied to colon tissues, in which the primary antibodies, (anti-EGFR antibody (abcam 
#52894), anti-mutant p53 antibody (abcam #32049) and anti-Bcl-2 antibody (abcam#182858), 
were used, followed by FITC conjugated anti-Rb IgG secondary antibody (stained for 2 hours at 
room temperature). The above process is the same for both IF and laser measurements.  
For dual staining of anti-EGFR-FITC and YOPRO, we first applied anti-EGFR-FITC (the 
same procedure as described for primary and secondary antibody labeling) to the lung tissue 
sections, then 0.1 mM YOPRO solution was applied for 20 minutes to the same tissue and rinsed 
with PBS solution twice before measurement. For staining of SYTOX Blue (ThermoFisher 
#S11348) and BOBO-1 Iodide  (ThermoFisher #B3582) in Fig. 5.26, SYTOX and BOBO-1 Iodide 
were dissolved in PBS at a concentration of 0.2 mM, following by the same staining procedures 
as for YOPRO.  
 
5.4. Results and discussion 
 
The detailed description of mirror fabrication/characterization, FP cavity assembly, and the 
laser emission-based microscope (LEM) setup can be found in Methods and Fig. 5.3. All the 
human tissue sections (cancerous and normal) were prepared under the same conditions with a 
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thickness of 15 μm, all of which were labeled with either YOPRO to target nucleic acids inside 
cells or FITC-conjugated antibodies that bind specifically to EGFR, mutant-p53, or Bcl-2, which 
can be expressed on the cell membranes, cytoplasmic organelles (endoplasmic reticulum, Golgi, 
and endosome), and nuclei. It should be noted that these antibodies are not only specific to the cell 
nuclei; however, clinical studies have identified the prescence of such biomarkers in the nuclei as 
a critical sign to determine the patients’ survival rate and prognosis158,163. Details of sample 
preparation and staining procedures can be found in Methods. 
 
5.4.1. Lasing in lung tissue with nucleic acids probe  
We began with the lung tissues labeled with YOPRO. Figs. 5.4(a) and (b) show the lasing spectra 
of cancerous and normal lung tissues under various pump energy densities when 0.5 mM YOPRO 
solution was used to label the tissues (H&E images in Fig. 5.5). A sharp lasing peak emerges 
around 547 nm. As a control experiment (not shown), no lasing was observed with pure YOPRO 
solution (without any tissue) at 0.5 mM, which is expected, as YOPRO has virtually no emission 
in the absence of nucleic acids. The spectrally integrated laser emission versus pump energy 
density extracted from Figs. 5.4(a) and (b) are both presented in Fig. 5.4(c), from which the lasing 
threshold of cancer and normal tissue are derived to be 21 μJ/mm2 and 32 μJ/mm2, respectively. 
Furthermore, in Fig. 5.4(d) we investigated the dependence of the lasing threshold on the 
concentration of the YOPRO solution used to stain the tissues at a fixed resonator length (15 µm) 
for both cancer and normal tissues. When the YOPRO solution concentration decreases from 0.5 
mM to 0.05 mM, the effective YOPRO concentration within a nucleus is expected to decrease 
accordingly, which leads to a drastic increase in the lasing threshold, especially for the YOPRO 
concentration below 0.25 mM. For all YOPRO concentrations, we find that the lasing thresholds 
for cancer tissues are consistently lower than those of normal tissues, which may attributed to the 
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higher amount of nuclear chromatin (and hence higher YOPRO concentrations) inside cancer cells 
(due to higher DNA replication activities)146,175,176. In addition, we notice that in Figs. 5.4(a) and 
(b) the lasing emissions remain single mode operation even at a pump energy density significantly 
higher than the respective lasing threshold. The full-width-at-half-maximum (FWHM) of the 
lasing emission is only 0.16 nm, limited by the spectrometer resolution. Such a single-mode lasing 
emission band is >100X narrower than that for the corresponding fluorescence, thus enabling 
highly wavelength-multiplexed detection. Although at an extremely high pump energy density (5X 
threshold) the YOPRO-stained tissue can support multi-mode lasing operation (see Fig. 5.6), the 
overall lasing band is still less than 10 nm wide, attesting to the intrinsic narrow gain profile for 
YOPRO, despite a wide fluorescence band. 
Fig. 5.4(e) shows the confocal fluorescence microscopy image of a nucleus in a cancer cell 
from the lung cancer tissue. Due to the low contrast of the fluorescence emission within the nucleus, 
we are unable to extract the exact locations having high nucleic acid concentrations. However, as 
visualized by the CCD images in Figs. 5.4(f) and (g), multiple sharp laser emissions with distinct 
and strong output against the surrounding background emerge like bright stars in the dark sky 
(“lasing stars”) from the specific sites having the highest abundance of nucleic acids. With the 
increased pump energy density, more sites having slightly lower abundance of nucleic acids start 
to lase (see Movie 1). Note that there may be fluorescence background emitting from the places 
that have relatively low concentrations of nucleic acids and therefore are unable to generate laser 
emission. However, such fluorescence is completely blocked by the top mirror that has >99.8 % 
reflectivity. Similarly, in Figs. 5.4(h-j) we also carried out a series of parallel experiments using a 
normal lung tissue and observed the same phenomena as in Figs. 5.4(f-g), except that the lasing 
stars start to emerge at a higher pump energy density and, at a given pump energy density, fewer 
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lasing stars are observed, both of which reflect the lower abundance of nucleic acids in a normal 




Figure 5.4. Lasing in lung tissue with nucleic acid staining dye. (a-b) Examples of lasing 
spectra of a human lung cancer tissue (a) and normal lung tissue (b), stained with YOPRO under 
various pump energy densities. Curves are vertically shifted for clarity. (c) Comparison of 
spectrally integrated (540 nm – 550 nm) laser output as a function of pump energy density 
extracted from the spectra in (a) and (b). The solid lines are the linear fit above the lasing threshold, 
indicating a lasing threshold of 21 μJ/mm2 for cancer tissue and 32 μJ/mm2 for normal lung tissue. 
The error bars (s.d.) are defined by considering the pump energy density variation of OPO pulsed 
laser during the measurements. (d), Lasing threshold with different concentrations of YOPRO used 
to stain the tissue. Three individual measurements were measured for each concentration at 
different sites, as presented individually in green and red squares. e, Confocal fluorescence image 
of a lung cancer nucleus (shown in green). (f-g) CCD images of the laser output from a nucleus in 
a lung cancer tissue (f) around (24 μJ/mm2) and (g) far above (50 μJ/mm2) the lasing threshold. 
The image shows clearly several sharp “lasing stars” within the nucleus, whereas the background 
fluorescence is significantly suppressed. h, Confocal image of a normal lung nucleus (in green). 
(i-j) CCD images of the laser output from a nucleus in a normal lung tissue (i) below (24 μJ/mm2) 
and (j) above (50 μJ/mm2) the lasing threshold. Note that e/h and g/j were taken from the same 
piece of tissue, but does not exactly represent the same cells. All the tissues in (a-j) were stained 
with YOPRO (0.5 mM in bulk staining solution) under the same preparation conditions. The 
dashed squares in (g) and (j) show the laser pump beam area in LEM. All scale bars, 5 μm. The 







Figure 5.5. H&E images of lung tissue used in Fig. 5.4. H&E images of the (a) lung cancer 
tissue and (b) normal lung tissue. Both human lung tissues were examined and diagnosed by 




Figure 5.6. Lasing spectra of YOPRO and EGFR-FITC at high pump. Lasing spectra of a 
lung cancer tissue labeled with 0.5 mM YOPRO (red curve) and a lung cancer tissue labeled with 
anti-EGFR-FITC. Both samples were pumped at a relatively high pump energy density, showing 
the existence of multiple laser modes. Excitation wavelength=465 nm.  
 
 
5.4.2. Characterization of LEM and lasing stars 
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To further characterize those “lasing stars”, in Fig. 5.7(a) we plot the laser emission profile 
of a single lasing star from the lung cancer tissue captured on the CCD. The FWHM is measured 
to be approximately 678 nm, providing a sub-micron and sub-cellular optical resolution (defined 
by the FWHM). Fig. 5.7(b) illustrates that two adjacent lasing stars separated by only 1.3 m can 
be well resolved. Comparison among bright field images, fluorescence images and laser-emission 
images using the identical cancer cells is given in Fig. 5.8, showing high spatial resolution and 
high contrast of the LEM, which is due mainly to the background suppression mechanism in the 
LEM (the background here is defined as the noise or low level signals within the cell nuclei).  
The insets of Figs. 5.7(c-f) illustrate that the sub-cellular lasing stars emerge progressively 
from a single to multiple lasing stars within the same pumping beam spot when the pump energy 
density increases gradually. The spectral analysis in Figs. 5.7(c-f) suggests that those lasing stars 
are independent of each other. Each of them is in single lasing mode operation, but may have 
slightly different lasing wavelengths due possibly to different local environments (such as nucleus 
thickness, refractive index, and gain distribution, etc.). Furthermore, spatial analysis shows that 
those lasing stars are the lowest order (0,0) Ince-Gaussian mode51,52. As exemplified in Figs. 5.7(c-
f), at a relatively low pump energy density, only those sites having the highest analyte 
concentration can lase. With the increased pump energy density, lasing from multiple sites can be 
observed. Conversely, multiple lasing sites can be “turned-off” down to a single lasing site by 
decreasing the pump energy density, signifying the repeatability and controllability of  lasing stars.  
Furthermore, spatial analysis shows that those lasing stars are the lowest order (0,0) Ince-
Gaussian mode51,52, which is due largely to the localization of nucleic acids (and hence the 
YOPRO). In order to validate this, we conducted a series of experiments by staining lung normal/ 
cancer tissues with FITC (non-specific dye) for comparison (Fig. 5.9). Despite the refractive index 
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differences, similar lasing modes (generally higher order Ince-Gaussian modes) were observed for 
both normal and cancer cells (Fig. 5.9 (d) and (e)), suggesting that FITC is equally distributed 
throughout the cell. In contrast, multiple independent lasing modes (lasing stars) can be observed 
in cells when labeled with YOPRO. 
 
Figure 5.7. Optical resolution of sub-cellular lasers under LEM. (a) Enlarged CCD image (left) 
of a single laser emission star from a human lung tissue stained with YOPRO. The intensity profile 
along the yellow dotted line (right) shows the FWHM of 678 nm. (b) Enlarged CCD image (left) 
of two adjacent lasing stars. The yellow square identifies the location of two lasing stars within 
the tissue. The intensity profile along the yellow dotted line (right) shows two well-resolved peaks. 
The smallest resolvable distance between two laser emissions is estimated to be better than 1 μm. 
(c-f) Lasing spectra of independent sub-cellular lasers within the same focal beam spot by 
increasing the pump energy density from (c) 20 μJ/mm2, (d) 30 μJ/mm2, (e) 40 μJ/mm2, to (f) 50 
μJ/mm2. The insets show the CCD images of corresponding laser emissions, in which (c) is an 
example of a single lasing star, (d) is an example of two independent lasing stars with different 
lasing thresholds, € is an example of three independent lasing stars with different lasing thresholds, 
and (f) is an example of multiple independent lasing stars emerging simultaneously at a high pump 
energy density. Note that the slight increase in the background emission beyond 560 nm in (c-e) 
is due to the fluorescence leaking out of the FP cavity caused by the reduced reflectivity of the 





Figure 5.8. Comparison of LEM and FL microscopy. Comparison of fluorescence microscopic 
image (a, d), bright field CCD image (b, e), and lasing-emission CCD image (c, f) of the identical 
cells. Two sets of examples from different tissue sections/cells (obtained from Patient 18) are given 
here in (a-c and d-f, respectively). Laser was only pumped within the dashed boxed regions in b, 
c, e and f. The bottom-left boxes in a, c, d and f show the enlarged images of the dashed boxed 
region in the respective figures. The difference between the high resolution and high contrast 
“lasing stars” (c, f) and low resolution and low contrast “fluorescent clouds” (a, d) is obvious. For 
detailed comparison, (g) and (h) show the intensity profile along the pink lines in images (a) and 
(c) (example 1), respectively. (i) and (j) show the intensity profile along the pink lines in images 
(d) and (f), respectively (example 2). The cancer tissues were stained with 0.1 mM YOPRO. Scale 
bars, 30 μm. Here the fluorescence images in Fig. 5.8 were first captured with a wide-field 
fluorescence microscope (without the top mirror), then immediately the corresponding lasing 




The significant difference between FITC and YOPRO in Fig. 5.9 supports the hypothesis 
that the lasing star is caused by the localization (concentration) effect of nucleic acids (and hence 
dyes). Consequently, the results in Fig. 5.7 provide an alternative method to quantify the analyte 
concentration in tissues (or cells) with a sub-micron spatial resolution by ramping the pump energy 
density. The image for each the pump energy density can be recorded so that the distribution of 
analyte relative concentration can be mapped and the histogram of the sites having different levels 
of analyte concentrations can be built, thus enabling more detailed characterization of tissues. 
 
 
Figure 5.9. Lasing modes of lung tissue stained with non-specific dye. (a) Lasing spectrum of 
lung cancer tissue stained (soaked) with non-specifc dye, fluorescein isothiocyanate (FITC). (b) 
CCD image of the lasing emissions from lung cancer tissue stained non-specifically with FITC. 
Multiple cells with different lasing mode profiles are observed. Those lasing modes are usually 
higher order Ince-Gaussian modes. However, for each cell, only one lasing mode exists. (c) CCD 
image of the lasing emission (multiple spatially isolated lasing stars) from cancer cells/tissue labled 
with YOPRO. Those lasing stars are independent of each other and are the lowest order Ince-
Gaussian mode. The tissues were stained with FITC or YOPRO with the same concentration (0.1 
mM) and pumped under 50 μJ/mm2. (d) Lasing modes observed from lung cancer cells/tissue non-
specifically stained with FITC. (e) Lasing modes observed from normal lung cells/tissue non-




5.4.3. Statistics of normal/cancer cell lasing thresholds  
According to the results in Fig. 5.4(d), the lasing thresholds for the cancer cell nuclei are 
generally lower than those for the normal cell nuclei. In particular, Fig. 5.4(d) shows that the 
binding of YOPRO to nuclear acids starts to saturate beyond 0.1 mM in cancer tissues. Thus, the 
largest difference in lasing threshold is achieved at 0.1 mM, which can be explored to distinguish 
between the cancer and normal tissues. In Fig. 5.10 we systemically investigated the lasing 
thresholds of 14 patients’ biopsies (including 10 sets of normal/cancer lung tissue, H&E images 
are given in Fig. 5.11), all of which were stained with 0.1 mM YOPRO. First, we present the 
statistics of lasing thresholds based on the 6 pairs of lung cancer tissues and normal lung tissues 
from the same patients (P1-P6) in Figs. 5.10(a) and (b), respectively. In particular, two types of 
non-small cell lung cancer, andenocarcinoma and squamous cell carcinoma (Fig. 5.10(c) for 
example), were investigated. At least 20 cells were randomly selected and measured within each 
tumor/normal tissue region for each patient. Interestingly, all cancer cells exhibit consistently a 
narrow lasing threshold range around 20 μJ/mm2. In contrast, the normal cells have a much wider 
threshold range, varying from 30 μJ/mm2 to 180 μJ/mm2. Next, we investigated the lasing 
thresholds based on 4 pairs of cancer and normal tissue from 8 different patients (4 normal: P7-
P10 and 4 cancer: P11-P14) in order to examine the sample-to-sample variations. Similar statistic 
results of lasing thresholds were observed in Figs. 5.10(d ) and (e). Both the p values of two sample 
t-Test between normal and tumor cells in both cases (same patient/ different patient) are < 0.005. 
The histogram of the lasing thresholds (N=472 cells) in Fig. 5.10(f) extracted from Figs. 
5.10 (a), (b), (d), and (e) shows clearly a cutoff threshold around 30 μJ/mm2 between the normal 
and cancer cells. As discussed previously, the stark difference in the lasing threshold is attributable 
to the different nucleic acid concentrations within cell nuclei177. As shown in the fluorescence 
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images in the inset of Fig. 5.10(f), normal cells undergo regular cell cycles/stages, whereas cancer 
cells are highly active abnormal cells that undergo endless divisions and DNA replication. The 
high proliferation of DNA (chromatins) in cancer cell nuclei will result in high nucleic acid 
concentrations, thus lower lasing thresholds.   
 
Figure 5.10. Statistics of cancer/normal cell lasing thresholds. (a) Statistics of tumor cell lasing 
thresholds from six individual lung cancer patients (P1, P2, P3, P4, P5, P6), labeled as Tumor 
tissue, T1-T6. For each patient, at least 20 cells were randomly selected and measured. (b) 
Statistics of normal cell lasing thresholds of normal lung tissues from the same six patients (P1-
P6) in a, labeled as Normal tissue N1-N6. (c) Exemplary H&E microscopic images of the two 
major types of non-small lung cancers used in this work, including andenocarcinoma (top) for P1-
P3 and squamous cell carcinoma (bottom) for P4-P6. Scale bars, 100 μm. (d) Statistics of tumor 
cell lasing thresholds from four different lung cancer patients (P7, P8, P9, P10), labeled as Tumor 
tissue, T7- T10. (e) Statistics of normal cell lasing thresholds of normal lung tissues from four 
different control patients (P11-P14), labeled as Normal tissue N7-N10. For each patient, at least 
20 cells were randomly selected and measured. The error bars (s.d.) in (a, b, d and e) are definded 
by the laisng threshold variation of 20 cells measured from each patients, respectively.The 
statistical box plots are also shown in the same figure in (a, b, d and e). The dashed purple lines in 
(a, b, d, and e) indicate the cutoff threshold of 30 μJ/mm2. (f) Histogram of all cancer/normal cell 
lasing thresholds (N=472) extracted from (a, b, d, and e). The insets show the confocal 





Figure 5.11. H&E images of lung cancer tissues used in Fig. 5.10. (a) H&E images labeled as 
Patient 1 (P1), Patient 2 (P2), Patient (P3), Patient 4 (P4), Patient 5 (P5), Patient 6 (P6), Patient 7 
(P7), Patient 8 (P8), Patient 9 (P9), and Patient 10 (P10), all of which were evaluated and diagnosed 
as lung cancer (Stage I and Stage II) by pathologists. P1-P3: lung andenocarcinoma. P4-P6: 
squamous cell carcinoma. (b) H&E images of normal lung tissues used in Fig. 4, labled as Patient 
1 (P1), Patient 2 (P2), Patient 3 (P3), Patient 4 (P4), Patient 5 (P5), Patient 6 (P6), Patient 11 (P11), 
Patient 12 (P12), Patient 13 (P13), and Patient 14 (P14). All scale bars, 50 m.  
 
 
5.4.4. Statistical comparison of LEM between normal/cancer tissues 
Based on the statistic results in Fig. 5.10(f), in Fig. 5.12 we employed the LEM to 
distinguish the cancer and normal tissues by mapping the laser emissions from nuclei in both 
cancer and normal tissues from 3 individual patients (P15, P16, P17, see Fig. 13 for H&E images). 
For each patient, 5 tissue sections (for both cancer and normal tissues) were scanned with the LEM 
over a field-of-view of 150 μm x 150 μm under a fixed pump energy density of 30 μJ/mm2, as 
99 
 
shown in Figs. 5.12(a-c), respectively. It is obvious that no or only a few lasing stars appeared in 
all normal tissue sections. In contrast, a large number of lasing stars were observed in cancer tissue 
sections, where isolated individual lasing stars and clusters of lasing stars were both present, since 
the pump energy density is above the lasing threshold for cancer cells.  
Quantitative analyses of the number of lasing cells using the LEM results in Figs. 5.12(a-
c) are plotted in Figs. 5.12(d-f) (note: a lasing cell is defined as the cell that has one or more lasing 
stars). Statistically significant differences between the cancer and normal tissues were achieved (p 
< 0.005 with two-sample t-Test), demonstrating the superior contrast and screening capability of 
the LEM. As comparison, in Fig. 5.14, we scanned the same tissues with confocal fluorescence 
microscopy. Figure 5.15 further analyzes the same confocal fluorescence images and shows that 
the fluorescence of the cancer and normal cells is very similar in intensity and spatial distribution. 
Those results in Figs. 5.14 and 15 suggest that confocal fluorescence microscopy is unable to 
distinguish/quantify cancer and normal tissues by nucleic acid expression by simply using 
fluorescence intensity distribution (Note that in Figs. 5.14 and 15, cancer and normal tissues can 
still be distinguished by the cell sizes/morphologies. However, for morphology based tissue 
evaluation, H&E (rather than fluorescence microscopy) is the golden standard. Later in Fig. 5.17 
and Fig. 18, we tested the LEM with early stage cancer tissues, where cancer/normal tissues cannot 
be distinguished by the cell sizes/morphologies). In comparison with histopathology, which is 
based on morphological assessment of cells and tissues, the LEM method that maps the lasing 
emissions from nuclei may provide a simpler, more systematic, and quantitative tool to 





Figure 5.12. Comparison and statistics of laser-emission microscopic images of normal/ 
cancer tissues. (a-c) LEM images by mapping the nucleic acids in normal and lung cancer tissues 
of (a) Patient 15, (b) Patient 16, and (c) Patient 17. For each patient, five normal/cancer tissue 
sections (frames) were scanned under a fixed pump energy density of 30 μJ/mm2. The white arrow 
in a points an example of a single lasing star in a normal tissue of Patient 1. NA= 0.42. All scale 
bars, 20 m. Each frame is 150 µm x 150 µm. The corresponding H&E images of the cancer tissues 
and normal tissues of the three patients are provided in Fig. 5.13. All three patients’ tissues were 
examined by pathologists  and diagnosed as lung cancer. (P15: Stage II, P16: Stage I, P17: Stage 
I lung cancer). (d-f) Statistics of the number of cells per frame that have laser emission from their 
respective nuclei for (d) Patient 15, (e) Patient 16, and (f) Patient 17 extracted from the LEM 
images in (a-c). Green/red bars are for the normal/cancer tissues, respectively. The error bars (s.d.) 








Figure 5.13. H&E images of lung cancer tissues used in Fig. 5.12. (a) H&E images labeled as 
Patient 15 (P15), Patient 16 (P16), Patient 17 (P17),all of which were evaluated and diagnosed as 
lung cancer (stage I and stage II) by pathologists.  (b) H&E images of normal lung tissues used in 






Figure 5.14. Confocal fluorescence microscopic images of normal and lung cancer tissues 
labeled with YOPRO. (a) Patient 15, (b) Patient 16, and (c) Patient 17. Each set of normal and 
lung cancer tissues were provided by the same patients as in Fig. 5.12. For confocal fluorescence 
imaging, only one tissue section from each patient is shown here for demonstration. Objective 




Figure 5.15. Intensity profile of normal/cancer cell under confocal images. (a, c) Confocal 
fluorescence images of tissue sections containing both cancer cells and normal cells within the 
same image for fair comparison. The samples were from the Patient 15 in Fig. 5, but different 
sections. Here we show only two images for example. (b, d) The intensity profile along the white 
dashed lines in image (a) and (c), respectively. Both (b) and (d) show that the fluorescence of the 
normal and cancer cells is very similar in intensity and spatial distribution, and therefore, cannot 
be used to characterize and classify tissues. All scale bars, 50 μm. 
 
In order to to establish the sensitivity and specificity of the LEM technique, we randomly 
selected 8 cancer patients and performed the LEM on both of their normal and cancer tissues. By  
using the same experimental condition and quantification methods as in Fig. 5.12, five tissue 
sections (frames) were scanned for each patient for both cancer tissue and normal tissue (a total of 
80 frames, N=80). The histogram of the number of the lasing cells per frame for normal tissues 
and cancer tissues are plotted in Figs. 5.16(a) and (b), respectively. Based on the number of lasing 
cells per frame, we generate the Receiver Operation Characteristic (ROC) curve in Fig. 5.16(c), 
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which has the area under the curve of 0.998. We found that the optimal threshold to identify a 
cancer tissue is “5 lasing cells per frame”, which corresponds to a sensitivity of 97.5%. Practically, 
the threshold can be adjusted for higher sensitivity or higher specificity.  
 
Figure 5.16. ROC calculation of LEM. (a) Histogram of frame counts based on the number of 
the lasing cells per frame in normal tissues from 8 different patients (P1, P3, P5, P6, P10, P15, P16, 
P17). For each patient, five frames (150 μm x 150 μm) were scanned under a fixed pump energy 
density of 30 μJ/mm2. (b), Histogram of frame counts based on the number of the lasing cells per 
frame in cancer tissues from 8 different patients (P1, P3, P5, P6, P10, P15, P16, P17). For each 
patient, five frames (150 μm x 150 μm) were scanned under a fixed pump energy density of 30 
μJ/mm2. (c), Receiver Operating Characteristics (ROC) curve based on the 80 frames (40 normal 
tissue sections, 40 tumor tissue sections) in (a) and (b).  The ROC curve is plotted by using the 
different lasing cell counts per frame. The area under the curve is 0.998. The inset shows the 
enlarged part of the ROC curve, in which the sensitivity of 97.5% is obtained based on the criterion 
of >5 lasing cells per LEM frame. 
 
 
5.4.5. Early stage lung cancer screening with LEM  
Using the threshold established above, we further demonstrated an important application 
of the LEM by examining early stage lung cancer tissues, which is regarded as the most critical 
yet challenging task in clinical histopathology. For this study, we used three samples from three 
patients, who were diagnosed as early stage lung cancer (in-progress lung cancer, see Figs. 5.17a-
c for the H&E images). The confocal fluorescence images are provided in the Fig. 5.18. It is 
obvious that the normal cells, in-progress cancer cells, and cancer cells are completely mixed 
within the whole tissue, making it very difficult to identify/differentiate according to cell 
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morphology and/or fluorescence intensity. In contrast, by using the LEM, cancer cells can be 
unambiguously identified within the tissue with a high contrast. For each patient, 5 sections were 
scanned with the LEM under a fixed pump energy density of 30 μJ/mm2, as shown in Figs. 5.17(d-
f). Quantitative analyses of the number of lasing cells using the LEM are also plotted in Figs. 
5.17(g-i). All three tissues are identified as cancer since all frames have more than 5 lasing cells. 
 
Figure 5.17. Laser-emission microscopic images of early stage lung cancer tissues. (a-c) H&E  
images of (a) Patient 18 (P18), (b) Patient 19 (P19), and (c) Patient 20 (P20), who are identified 
as in-progress or early stage lung cancer. (d-f) The corresponding LEM images by scanning the 
nucleic acids of the tissues from the same three patients. For each patient, five tissue sections 
(frames) were scanned under a fixed pump energy density of 30 μJ/mm2. (g-i) Statistics of the 
number of cells having lasing emission from nuclei extracted from the LEM images. The error 
bars (s.d.) are defined by the variations in lasing cell counts. NA= 0.42. Scale bars for (a-c) 100 






Figure 5.18. Confocal fluorescence microscopic images of early stage lung tumor tissues 
labeled with YOPRO. (a) Patient 18, (b) Patient 19, and (c) Patient 20. For confocal fluorescence 
imaging, three different sites/sections from each patient are shown here for demonstration. The 
tissues used here were from the same patients as in Fig. 5.17 (same tissues but different sections). 











5.4.6. Multiplexed immuno-lasing in lung cancer tissues  
Moving a step forward, we aim to improve the prognostic prediction of cancer patients by 
demonstrating immunodiagnosis capability of the LEM. Here in Fig. 5.19 we studied the lasing 
emission using EGFR antibody conjugated with FITC (anti-EGFR-FITC) to target nuclear EGFR 
(n-EGFR) expressed in the same lung cancer tissue used in Fig. 2. Similar to the YOPRO case in 
Fig. 5.14(a), Fig. 5.19(a) shows single-mode lasing emission with an FWHM of about 0.16 nm 
when the pump energy density is slightly above the threshold. Although with the increased pump 
energy density the second mode emerges, the lasing band is only about 8 nm, much narrower than 
the corresponding fluorescence band (>60 nm.). The spectrally integrated laser emission versus 
pump energy density extracted from Fig. 5.19(a) is presented in Fig. 5.19(b), showing a lasing 
threshold of approximately 67 μJ/mm2. We further investigated 10 samples from 5 lung cancer 
patients with nuclear EGFR positive response (Patients: P21-P25. Details are given in Fig. 5.20). 
The measured lasing thresholds is plotted in Fig. 5.19(c). The variation in the lasing threshold is 
caused by the different degrees of EGFR expression (hence FITC concentration) in each cell 
nucleus. For comparison, it is difficult for conventional IF microscopy (Fig. 5.19(d)) to pinpoint 
the exact locations within the nucleus that have high EGFR concentrations. Similar to the YOPRO 
lasing case studied previously, with the laser emission significant improvement is achieved in the 
imaging contrast and the capability to locate the spots of high EGFR concentrations with a sub-
micron resolution, as shown in Figs. 5.19(e) and (f). 
With the sub-cellular lasing from n-EGFR achieved in Fig. 5.19, we now applied the LEM 
to distinguish the lung tissues with and without n-EGFR in Fig. 5.21. We prepared two types of 
lung cancer tissues, adenocarcinoma with n-EGFR (Tissue type #1) and adenocarcinoma without 





Figure 5.19. Lasing in lung cancer tissue with anti-EGFR-FITC. (a) Examples of lasing spectra 
of a human lung cancer tissue with n-EGFR expression stained with anti-EGFR-FITC under 
various pump energy densities. Curves are vertically shifted for clarity. (b) Spectrally integrated 
(530 nm – 540 nm) laser output as a function of pump energy density extracted from the spectra 
in (a). The solid lines are the linear fit above the lasing threshold, indicating a lasing threshold of 
67 μJ/mm2. (c) Histogram of n-EGFR-FITC lasing thresholds measured from 10 cells (samples) 
out of 5 lung cancer patients (patients P21-P25: including squamous cell carcinoma and 
andenocarcinoma tissues).  The error bars (s.d.) in both (b) and (c) are defined by considering the 
pump energy density variation of OPO pulsed laser during the measurements. (d) Confocal 
microscopic image of a cell with n-EGFR expression in the lung cancer tissue. (e) CCD images of 
the laser output from the same lung cancer tissue above the lasing threshold (125 μJ/mm2). The 
image shows clearly several “lasing stars” corresponding to the highest concentrated EGFR 
locations within the nuclei. The dashed square shows the laser pump beam area in LEM, which is 
focused on only one of the cells in the tissue. Note that (d) and (e) are not from the identical cells, 
but from the same piece of tissue.  (f) The intensity profile along the yellow dotted line (inset) 
shows the FWHM is measured to be 860 nm. All the tissues were stained with anti-EGFR-FITC 







Figure 5.20. H&E images of the lung tissues used for immuno-laser experiment in Fig. 5.19. 
(a) Lung cancer patients diagnosed with nuclear-EGFR expression (P21-P23 stage I 
andenocarcinoma; P24-P25 stage I squamous cell carcinoma; P26: stage II andenocarcinoma). 
Only P26 show negative response for lasing, P21-P25 all have EGFR-FITC lasing. (b) Lung cancer 
patients diagnosed without nuclear-EGFR expression (P27-P29: stage I andenocarcinoma). (c) 
Normal lung tissues from healthy patients (P30-P32). All human lung tissue were examined and 












The exemplary lasing spectra of Type #1 (red curve) and Tissue #2 (blue curve) tissues 
when stained with anti-EGFR-FITC are shown in Fig. 5.21(a). As expected, laser emission at 537 
nm is obtained in Tissue #1 with a pump energy density of 80 μJ/mm2; however, no lasing from 
Tissue #2 can be observed from the entire tissue when pumped with the same energy density. This 
result indicates that cells having EGFR expression only on the membranes or other cytoplasmic 
organelles are not capable to provide sufficient gain to lase due to relatively low abundance of 
EGFR (and hence FITC). To validate the above experiments, we examined a total of 12 human 
patients with 3 tissue sections from each patient, including 6 lung cancer patients with n-EGFR 
and 6 patients without n-EGFR (3 normal and 3 lung cancer diagnosed without n-EGFR). Details 
of the 12 patients are provided in Fig. 5.20, labeled as patient P21-P32. Among all the 6 patients 
with n-EGFR, 5 of them showed positive lasing emissions (P21-P25). For all normal patients (P30-
P32) and those having lung cancer but without n-EGFR (P27-P29), none of them showed lasing 
emissions from anti-EGFR-FITC. The statistic results are plotted in 5.21(b). The corresponding 
IHC image of both types of tissues in 5.21(b)  (right column) confirm that Type #1 tissue has a 
significant amount of EGFR within most cell nuclei, whereas Type #2 tissue does not have any 
EGFR expression within the cell nuclei (but does have EGFR expressed on the cell membrane). 
In order to further confirm that FITC lasing is only from the expression of EGFR in the 
nucleus, co-localization of EGFR and nucleus lasing signals from sub-cellular locations is critical, 
which not only verifies the presence of n-EGFR in a nucleus but also makes it easier for computer-
aided imaging processing in the future. To demonstrate co-localization, both Type #1 and Type #2 
tissues were dual-stained with YOPRO and anti-EGFR-FITC (see Methods). It is apparent that we 




Figure 5.21. Multiplexed lasing in lung cancer tissues. (a) Lasing spectra of Type #1 (red curve) 
and Type #2 (blue curve) tissues stained with anti-EGFR-FITC. Pump energy density=80 μJ/mm2. 
(b) Statistics of the EGFR lasing results for positive and negative n-EGFR lasing from 12 patients 
(P21-P32). Details and H&E images are provided in Fig. 5.20. (i) Brightfield IHC image of a 
human lung cancer tissue with n-EGFR (Tissue type #1). (ii) Brightfield IHC of a human lung 
cancer tissue without n-EGFR overexpression (Tissue type #2). (c) Lasing spectra of a Type #1 
tissue dual-stained with YOPRO and EGFR-anti-FITC. The laser was focused on a single nucleus 
within the lung cancer tissue. The pump energy density was set above the threshold for both 
YOPRO and FITC under single excitation wavelength. The inset CCD image is the demonstration 
of a n-EGFR laser emission, which indicates that EGFR co-localizes with the nucleus. (d) Lasing 
spectra of a Type #2 tissue dual-stained with YOPRO and anti-EGFR-FITC. The laser was focused 
on a single nucleus within the lung cancer tissue. Note that the slight increase in the background 
emission beyond 550 nm in (a) and (c) is due to the fluorescence leaking out of the FP cavity  







EGFR expressions in nucleus and cytoplasm, as a result of the huge spectral overlap between 
YOPRO and FITC (Fig. 5.22). In contrast, lasing signals of the two dyes can be observed and 
distinguished spectrally for Type #1 tissue. As shown in Fig. 5.21(c), two sharp lasing peaks appear 
at 537 nm and 547 nm when the tissue was pumped at the nucleus, which is the evidence of dual 
lasing from both EGFR and nucleic acids. The inset of Fig. 5.21(c) shows a CCD image, which 
confirms the presence of EGFR in the nucleus. Note that since the lasing threshold of FITC is 
much higher than that of for YOPRO, the lasing intensity from FITC is lower than that from 
YOPRO under the same pump energy density. Also note that even at higher pump energy densities 
at which higher order modes may emerge, the lasing spectra of YOPRO and FITC can still be 
distinguished due to their very narrow emission bands. As a negative control, for Type #2 tissue 
(Fig. 5.21(d)) only lasing spectrum from YOPRO was obtained when the tissue was pumped at the 
nucleus, no lasing signal from EGFR was observed, indicating that no EGFR or very low EGFR 
exists in the nucleus. 
 
 
Figure 5.22. Fluorescence emission spectra of YOPRO and FITC. (a) Normalized fluorescence 
emission spectra of FITC (blue curve) and YOPRO (red curve) when they were used individually 
to stain the tissue. Huge spectral overlap (~100 nm) between the two dyes is obvious.  (b) 
Significant fluorescence spectra of mixture solutions of FITC and YOPRO with various molar 
ratios. Note that YOPRO fluorescence emission can be detected only when it binds to nucleic acids. 
Therefore, the emission in (b) is predominantly from FITC. (c) Fluorescence spectra measured 
from lung cancer tissues by staining the tissues with the mixture solutions of FITC and YOPRO at 
various molar ratios. It is obvious that the fluorescence emission from FITC and YOPRO cannot 




5.4.7. Applications in colon cancer tissues  
Finally, we applied the LEM to other types of tissues and proteomic biomarkers to validate 
its broad utility. In Fig. 5.23 we examined three different important cancer biomarkers (EGFR, 
p53 and Bcl-2) in human colon cancer tissues. For the purpose of tissue characterization, Figs. 
5.23(a-c) present the IHC and confocal IF images of a colorectal cancer tissue labeled with the 
corresponding antibodies (i.e., anti-EGFR, anti-mutant p53, and anti-Bcl-2), showing a high 
amount of EGFR, p53 and Bcl-2 in the nuclei of the respective tissues. Similar to the procedures 
used previously, the lasing emissions from those colon tissues labeled with anti-EGFR-FITC, anti-
mutant p53-FITC, and anti-Bcl-2-FITC were achieved in Figs. 5.23(d-f), when the nuclei were 
pumped. Our results show that lasing is achieved when there exist a high amount of biomarkers 
within the nuclei, which can be used for immunodiagnosis of various nuclear biomarkers. Despite 
the existence of multiple lasing peaks at the high pump energy density, the laser emission band is 
still approximately only 5 nm, showing the potential capability of multiplexed detection. The 
corresponding lasing threshold curves are presented in Figs. 5.24(a-c), showing that the lasing 
threshold is on the order of 200 µJ/mm2.  
Besides cancer cells, the same technology can be extended to stroma cells (cancer-
associated fibroblasts) that have overexpressed biomarkers. For example, Fig. 5.25 gives a lasing 
example using a colon tissue expressed with Bcl-2. Recent reports have revealed that the 
interaction between stromal cells and tumor cells plays a major role in cancer growth and 
progression178. Moreover, stromal gene expression have also demonstrated to define poor-prognosis 
subtypes in several cancers179,180. Therefore the capability to observe tumor stroma lasing will be of 





Figure 5.23. Lasing in colon cancer tissues with FITC conjugated antibodies. (a-c) Bright field   
IHC and confocal microscopic images of human colon cancer tissues with n-EGFR (a), n-p53 (b), 
and n-Bcl-2 (c) overexpression. (d-f) Lasing spectrum of colon cancer tissue prepared with anti-
EGFR-FITC (d), anti-p53-FITC (e), and anti-Bcl-2-FITC (f). The insets in d-f shows the CCD 
image of representative “lasing stars” from the colon tissues when pumped at the nuclei. Pump 
energy density=220 μJ/mm2, 280 μJ/mm2, and 300 μJ/mm2 for (d)-(f), respectively. Corresponding 
threshold plots can be found in Fig. 5.24. In total, 3 tissue samples from 3 different colon 




Figure 5.24. Lasing threshold of colon cancer tissue labeled with antibodies. Spectrally 
integrated (530 nm – 540 nm) laser output as a function of pump energy density for colon cancer 
tissue labeled with (a) anti-EGFR-FITC, (b) anti-mutant  p53-FITC, and (c) anti-Bcl-2-FITC 
antibodies. The fitted lasing threshold is about 182 μJ/mm2, 200 μJ/mm2, and 230 μJ/mm2 for a, 
b, and c, respectively. Solid lines show the linear fit above the threshold. Tissue thickness=15 μm. 






Figure 5.25. Lasing in tumor stroma. (a) IHC image of a colon cancer tissue labeled with anti-
Bcl-2 antibodies, which shows high expression of Bcl-2 in the tumor stroma. (b) Confocal IF 
image of the colon stroma labeled with anti-Bcl-2-FITC. (c) CCD image showing two lasing stars 
from a stroma cell nucleus in a colon tissue. Note that (a-c) are not from the same cells, but from 




In this chapter, we have developed a laser-emission based imaging tool (LEM) that takes advantage 
of the high intensity, high background suppression, and high spectral/spatial resolution of the laser 
emission. We have further tested its validity in early stage cancer diagnosis and evaluation of 
various nuclear biomarkers (nucleic acids, EGFR, p53, and Bcl-2) in human cancer tissues, which 
may significantly benefit the current clinical practice by providing complementary information 
that the conventional H&E, IHC, and IF are unable or difficult to obtain. Laser-emission-based 
cancer screening and immunodiagnosis might find use in precision medicine and facilitate research 
in cell biology. 
As an outlook, below we discuss a few possible areas that deserve further exploration in 
the near future. (1) Conventional methods (H&E, IHC and IF) are known to be more subjective 
and may cause significant variations in tissue evaluation from one pathologist to another166-168,181. 
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The LEM can potentially provide a means to quantify the number of sites within a cell that have 
different levels of biomarker expression and the number of cells that express high nuclear 
biomarkers. In Fig. 5.12, each lasing cell was counted only once even though there might be 
multiple lasing stars present inside the lasing cell. Despite this significantly simplified way of 
categorization, the LEM is already able to distinguish cancer and normal tissues. On the other hand, 
we have discussed that the lasing stars in cancer tissues may have different lasing thresholds due 
to different biomarker concentrations. By ramping the pump energy density, the histogram of the 
lasing stars with different thresholds can be constructed, which may allow us to sub-categorize the 
cancer tissue (e.g., in terms of severity and sensitivity to therapies). We will work closely with 
pathologists to develop algorithms that can make best use of this new information for more 
objective evaluation of cancer tissues. (2) Fundamentally, through the LEM we have found that 
there exist multiple sites within a nucleus that have high biomarker expressions. Further 
interdisciplinary collaboration is needed to elucidate mechanisms of the occurrence of those spots 
and how to make use of them in cancer diagnosis/prognosis. 
 (3) While dual detection (2-plexed detection) was achieved in this work, there is no doubt 
that the LEM platform is capable to accommodate more fluorophores. For instance, in Fig. 5.26(a) 
lasing emission from a third dye (high-affinity nucleic acid dye - SYTOX Blue) was achieved, 
which is centered on 500 nm with a band width less than 5 nm. Furthermore, we demonstrate that 
at least four lasing emission wavelengths can be clearly distinguished within the range of 500 nm 
– 550 nm in Fig. 5.26(b). In the future, high wavelength multiplexicity of the lasing emission will 





Figure 5.26. Four color multiplexed lasing in tissue. (a) Lasing spectra of lung cancer tissue 
labeled with 0.25 mM SYTOX Blue (SYTOX) nucleic acid dye. The inset shows the CCD image 
of lasing stars from several nuclei simultaneously. Pump energy density=140 μJ/mm2. Scale bar, 
40 μm. (b) Superposition of the lasing spectra of four dyes, SYTOX, BOBO-1 iodide, FITC 
(conjugated with EGFR), and YOPRO, shows multiple wavelength channels can be 
accommodated even within a 50 nm band, suggesting the possibility of highly wavelength-
















Monitoring Neuronal Activites and Networks with Neuron Lasers 
So far in Chapter 2 to Chapter 5 we have demonstrated the potential applications of optofluidic 
lasers in various tissues. Finally, here in Chapter 6 we present an ongoing research work which 
will show potential for future monitoring of biological networks and tissues. Thus here we 
investigate the lasing properties of living cells in a biological network (multicellular network). 
This is particularly significant since cellular networks are the most fundamental formation of all 
tissues in living body. The ability to study the multicellular functions in networks will provide 
more insights for tissue engineering as well as the development of  improved diagnostics and 
therapeutics. Therefore, here we used living neurons as an example to demonstrate lasing in 
neuronal networks (neuron lasers). Optical recording of calcium transients during spontaneous 
neuronal activities was demonstrated via “neuron lasers” with up to 1000-fold improvement in 
sensitivity. This work provides a novel approach to monitoring neuronal network dynamics and 
brain-on-chip neurophotonic applications.     
6.1 Introduction 
Calcium ions generate versatile intracellular signals that govern prevalent physiological 
processes and critical functions in several cell types, especially neurons182. For decades, calcium 
imaging has been a powerful approach to monitoring the calcium dynamics during neuronal 
activities in huge networks183,184. In particular, recent studies have revealed that spontaneous 
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calcium spikes have huge implications on neurological disorders, neuronal signaling, and brain 
circuits185. However, current techniques such as fluorescence-based measurements are not 
sufficiently sensitive to detect or monitor the extremely subtle changes in calcium concentrations, 
as the relative fluorescence change (ΔF/F) is usually on the order of only 0.1186,187. Consequently, 
spontaneous neuronal activities are often missed as noise. A better ability to visualize  
spatial/temporal transients in cytosolic calcium levels resulting from spontaneous neuron activities 
will deepen and broaden our understanding of the pathophysiological mechanisms in neuroscience.  
To date, laser emission from biological materials have demonstrated the distinct 
advantages over fluorescence, as described in the previous chapters. In particular, laser emission 
possesses the ability to amplify very subtle changes at the molecular level, leading to orders of 
magnitude increase in detection sensitivity and imaging contrast6. Taking advantage of such 
features, here we aim to detect the subtle Ca2+ concentration changes in live primary neurons by 
laser emissions. Lasing in neurons with a sub-cellular and single-spike resolution were explored 
to analyze the intracellular calcium dynamics during spontaneous neuronal activities in vitro. In 
addition, lasing from single isolated neurons and from neurons within a neuronal network were 
both recorded, showing 100-1000 times improvement in the sensing signal. 
6.2. Experimental concept and design  
Fig. 6.1(a) illustrates the concept of such a neuron laser, in which the primary cortical 
neurons labeled with Oregon Green BAPTA-1 (OGB-1) is sandwiched inside a Fabry-Pérot 
microcavity formed by two dielectric mirrors. The inset shows the fluorescence image of neurons 
stained with OGB-1 on top of a mirror. Microspheres (5 µm in diameter) were used as spacers to 
ensure the cavity length for cellular lasing. As illustrated in Fig. 6.1(b), the unique threshold 
behavior of the neuron laser can be explored for sensitive detection of spontaneous neuronal 
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activities. At the resting potential, no neuronal activity and hence no Ca2+ spiking occur. Therefore, 
the laser is operated below its threshold and only extremely weak background is observed. When 
a spontaneous spike occurs, the increase in Ca2+ concentration results in the emergence of the 
lasing emission. This sharp cut-off characteristic before and after lasing ensures orders of 
magnitude improvement in detection sensitivity. 
 
 
Figure 6.1. Concept of optical recording with neuron laser. (a) Schematic of the experimental 
configuration of a neuron laser. The inset shows the fluorescence image of OGB-1 labeled primary 
rat cortical neurons cultured on mirrors. Scale bar, 30 µm. (b) Output intensity from neuron lasers 
as a function of intracellular Ca2+ concentration. Under the fixed pump intensity, only when 
intracellular Ca 2+ reaches above the baseline concentration (~50 nM) can the lasing emission start 
to emerge. (c) The protocol of image processing for monitoring neuronal activities. Different 
region of interest (ROI) were selected on the LEM images over a period of time, then calculated 
by the algorithms.   




For this particular research, primary cortical neurons from rat (Thermofisher #A15586) 
were selected as our model. The mirrors were first autoclaved and coated with poly-D-lysine and 
laminin (Sigma #127-2.5) for 30 mins, to ensure the cell growth and attachment. The cortical 
neurons were then cultured on top of the mirrors within cell culture medium (Thermofisher 
#21103049) and incubated at 37C for 3-5 days before further observation.  The neurons were then 
stained with Oregon Green BAPTA-1 (OGB-1) by dissolving the OGB-1 AM ester in pluronic 
acid pluoronic-127 (in DMSO) to reach a final concentration of 25 uM in the culture medium. 
After incubation for 3 hours, the neurons were washed with PBS before measurements.  
Optical recording of neurons was performed by collecting series of laser emission images 
from high speed CCD (frame rate of 5 fps). The optical setup is shown in Fig. 6.1(c). The recorded 





where L(t) is defined as the measured laser emission intensity from a certain ROI on the LEM 
image.  R(t) is defined as the variation (relative changes) of laser emission intensity over a period 
of time. Lb is defined as the minimum laser emission intensity within the period of time, which is 
used as the baseline signal here. The algorithms was developed in Python, in which the baseline 
of the selected neuron emission is the minimum intensity within the time period.  The intensity for 
each region of interests (ROI) is calculated by using the average intensity of the surrounding pixels 
(9 pixel in total) regarding the ROI.  The excitation wavelength is 475 nm while using an OPO 




6.4. Results and discussion 
6.4.1. Lasing with calcium indicators 
OGB-1 is known as a calcium indicator and has higher fluorescence (or laser gain) in the 
presence of Ca2+. The fluorescence emission spectra of OGB-1 with and without the presence of 
Ca2+ is shown in Fig. 6.2(a), in which the relative fluorescence change (ΔF/F) is less than 0.1. As 
a comparison, the laser emission spectra of OGB-1 (pure dye) and OGB-1 with Ca2+ is plotted in 
Fig. 6.2(b). We can clearly see that no emission can be observed in pure OGB-1 (blue curve), 
however, a huge laser emission is generated when OGB-1 is mixed with Ca2+. In contrast to Fig. 
6.2(a), the relative intensity change is more than 100, which is 3 orders magnitude larger than 
conventional fluorescence. The amplification process of laser emission can thus be applied to 
monitor those subtle interactions of intracellular biomolecules in living cells. The corresponding 
spectrally integrated laser emission versus pump energy density presented in Fig. 6.2(c) shows the 
lasing threshold of approximate 120 μJ∕mm2. To characterize the OGB-1 laser, in Fig. 6.2(d) we 
investigated the lasing threshold of pure OGB-1 (50 M) mixed with various concentrations of 
free Ca2+. Note that here in Fig. 6.2 we used this concentration to mimic neurons because the 
effective intracellular OGB-1 concentration in neurons is measured to be 50 M in average during 
our staining process. It is shown that the lasing threshold increases with the decreased Ca2+ 
concentration, which is expected. In particular, a drastic difference in the lasing threshold can be 
seen when the Ca2+ concentration is in the range of 50 nM – 100 nM, which suggests that OBG-1 
and its lasing emission can be used to monitor the subtle transients of spontaneous calcium spike 
activities, as the spontaneous Ca2+ concentration in neurons is within the same range of 50 nM – 




Figure 6.2. Lasing with calcium indicator OGB-1. (a) Fluorescence emission spectra of pure 
OGB-1 (blue curve) and OGB-1 mixed with 100 nM of free Ca2+ (red curve). (b) Lasing emission 
spectra of pure OGB-1 (blue curve) and OGB-1 mixed with 100 nM of free Ca2+ (red curve) under 
a pump energy density of 280 μJ∕mm2. (c) Spectrally integrated (530 nm – 545 nm) laser output as 
a function of pump energy density extracted from the spectra in (b). The solid lines are the linear 
fit above the lasing threshold, indicating a lasing threshold of 120 μJ/mm2. (d) Lasing threshold 
calibration of pure dye (OGB-1) mixed with different free Ca2+ concentrations. The shaded green 
area depicts the spontaneous calcium spiking region (50-100 nM). The excitation wavelength is 




6.4.2. Lasing in living neurons  
 
In Fig. 6.3(a) we demonstrated for the first time, a “neuron laser” when the neuron was 
labeled with 25 M OGB-1. A single mode lasing profile was first observed when the pump energy 
density is slightly above the lasing threshold. Multiple lasing modes emerge as the pump increases 
in Fig. 6.3(a). The inset shows an example of a bright field image of a single neuron with laser 
emissions within the cell soma. The corresponding spectrally integrated laser emission versus 
pump energy density presented in Fig. 6.3(b) shows the lasing threshold of approximate 150 
μJ∕mm2 for the neuron at the resting potential. As visualized by the CCD images in the inset of Fig. 
6.3(b), no lasing was observed when the pump was below 150 μJ∕mm2.  
In contrast, sharp lasing emission emerges as the pump intensity increases, while the signal-
to-background ratio is measured to be 500. Subcellular laser emissions can be observed only from 
specific sites in the neuron.  Note that although the neuron in Fig. 6.3(a) was at the resting potential 
(no spontaneous Ca2+ spiking), the lasing emission could still be obtained at relatively high pump 
energy densities (i.e., >150 μJ∕mm2). However, the lasing threshold is expected to be much lower 
when the neuron undergoes spiking or firing behaviors. Furthermore, we investigated the spatial 
resolution of such neuron laser images in Fig. 6.3 (c). The inset shows that lasing emission could 
be achieved from both the soma and dendrites of neuron, while the FWHM was measured to be 









Figure 6.3. Lasing in living neurons. (a) Lasing spectra from a single neuron in vitro labeled 
with 25 µM OGB-1 under various pump energy densities at the resting potential. The inset shows 
the bright field a CCD image of a single neuron with sub-cellular laser emissions in the soma, as 
indicated by the arrow. (b) Spectrally integrated laser output as a function of pump energy density 
extracted from (a). The solid lines are the linear fit above the lasing threshold, indicating a lasing 
threshold of 150 μJ/mm2. (c) CCD image of laser emissions from neurons. The dashed line 
measures the lasing profile over a single dendrite. (d) The FWHM of extracted from the dashed 
line in (c), which gives a submicron resolution of 950 nm.  
 
 
6.4.3. Calcium imaging of spontaneous neuronal activity  
Moving forward, here we aim to demonstrate optical recording/imaging of intracellular 
spontaneous calcium signals in neurons by using neuron laser emissions. As such, the pump energy 
density was fixed at 150 μJ/mm2. As discussed previously, at the resting potential, no lasing 
125 
 
emission would be observed. However, with the spontaneous neuronal activities, calcium spikes 
occur, resulting in the emergence of lasing emission. The laser emission CCD images of a single 
isolated neuron is shown in the inset of Fig. 6.4(a). The calcium transients of individual neuron 
caused by spontaneous soma activity was recorded over 90 seconds, as plotted in Fig. 6.4(a). 
Significantly, the relative changes in lasing intensity (ΔL/L), where L is defined as the baseline 
intensity before lasing and L is the lasing emission intensity above the background, ranges from 
20 to 50, >100-fold improvement over the traditional fluorescence based measurement. In order to 
validate that all the CCD images recorded are from lasing emissions, we selected two 
representative signals at 48s and 82s, as plotted in Figs. 6.4(b) and (c), respectively.  
 
 
Figure 6.4. Optical recording of spontaneous activity in single neuron. (a) Optical recording 
of calcium transients caused by spontaneous neuronal activity over 90 seconds measured from 
neuron. The inset shows the CCD image of laser emission from a single neuron. (b) Lasing 
spectrum measured at 48 sec. (c) Lasing spectrum measured at 82 sec. The red shift of lasing peak 






6.4.4. Biologically controlled lasing in neuronal networks 
Finally, lasing in neuronal networks was achieved. Based on the similar protocols, the 
calcium transients of neurons within a neuronal network was recorded and analyzed. Two types of 
intra-cellular interactions are presented here in Fig. 6.5, resulting in significant changes in neuron 
laser output. First, as shown in Fig. 6.5(a), the CCD image (left) clearly shows the laser emissions 
of three individual neurons (n1, n2, and n3). The calcium transients of neurons in neuronal 
networks were recorded simultaneously in Fig. 6.5(b), in which the ΔL/L can be as high as 100 
due to the recurring stimuli and interactions among neurons. The time traces also show correlation 
between n1, n3, and n3 in calcium spikes. Secondly, another example is given in Fig. 6.6(a), the 
calcium transients of neurons (n1 and n2) in neuronal networks were recorded simultaneously. 
According to the two inset CCD images in Fig. 6.6(a), we can clearly see that only n1 show 
significant lasing emissions at 22s (blue trace), while n2 is completely dark with no lasing signal. 
Conversely, only n2 show lasing emissions at 32 s (red trace), while n1 turns completely dark and 
no lasing is observed. This is the result of interactions (energy transfer) between two neurons, 
suggesting that neuron lasers can be biologically switched on/off based on intercellular calcium 
dynamics. In order to validate that all the CCD images recorded are from lasing emissions, we 
selected two representative signals at 22 s (blue curve) and 32s (red curve), as plotted in the inset 





Figure 6.5. Optical recording in neuronal networks. (a) CCD image of laser emission from a 
neuron network formed by 3 neurons (n1, n2, and n3). (b) Optical recording of calcium transients 
caused by spontaneous neuronal activity over 90 seconds measured from neuron-n, neuron-n2, and 






Figure 6.6. Interactions of neuron lasers in neuronal network. (a) Optical recording of calcium 
transients caused by spontaneous neuronal activity over 90 seconds measured from neuron-n1 and 
neuron-n2 in a network. The above CCD images show the laser emission switching between two 
neurons (n1 and n2). (b). Lasing spectrum measured at 22 sec from n1. (c). Lasing spectrum 
measured at 32 sec from n2. Scale bars, 15 µm.  
 
6.5. Conclusion  
For the first time, we demonstrated a neuron laser and employed laser emission to detect 
the subtle transients of intracellular calcium dynamics in neurons in vitro. Lasing in single neuron 
and neuronal networks were biologically controlled by spontaneous neuronal activities. Calcium 
imaging and recording of spontaneous neuronal spike activities were demonstrated, in which the 
relative changes (ΔL/L) were significantly improved 100-1000 fold in comparison with that 
obtained by fluorescence based measurement. Highly interaction and correlation between neurons 
also resulted in complex lasing emission spikes. Our work not only opens the door to optical 
recording of intracellular dynamics in neuronal networks, but provides an ultra-sensitive detection 






Summary and Outlook 
In this dissertation, we have successfully developed the first biolasers at the tissue level by using 
different micro-cavities and several types of tissues. Furthremore, we evidently demonstrated that 
the proposed tissue lasers can be applied to a variety of tissues to differentiate various diseases and 
cancers for future clinical applications. Our work represents a critical milestone to implement 
optofluidic lasers in tissues, which opens a door to a plethora of applications in bioimaging and 
biosensing with superior contrast and high spectral/spatial resolution.  
In contrast to conventional fluorescence, the laser output from tissues provides a number 
of optical parameters unseen in fluorescence, such as the lasing threshold of various biomarkers, 
lasing mode spatial distribution, lasing mode competition, and lasing gain clamping. We will 
conduct further investigations to understand how those parameters reflect the underlying biological 
and physiological processes of cancerous tissues as well as to achieve better spectral and spatial 
resolution. Other potential applications will also be explored, including, but are not limited to, Pap 
smear stain examination, intraoperative image-guided neurosurgery and tumor resection, and 
Fluorescence In-Site Hybridization (FISH). Technically, currently the FP tissue laser is operated 
in a multi-mode regime. While the lasing emission band is much narrower than that in fluorescence, 
it is still about 10 nm wide, which limits multiplexing capability. Eventually a single-mode tissue 
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laser will be pursued using either shorter cavity length or external optical feedback, in which case 
the lasing band can be far below 1 nm (currently 0.2 nm, limited by the spectrometer resolution).  
However, there are a few challenges which needs to overcome in the future. First, advanced 
design of biocompatiable and wearable laser cavity is required to develop in vivo lasing 
experiments in animals and human. The current setup does not allow to perform in vivo sensing; 
however, by using spasers or distributed feedback lasers, we may possible to achieve that in the 
future. Secondly, 3D information and z-sectioning is very important for tissue imaging while laser 
emission only provides a stacked information of the tissue. By using fiber-probes, we may be able 
to render or map the cells in different directions to gain the 3D insights. Thirdly, laser requires the 
fluorophore to reach a certain concentration in order to overcome the threshold; however, the sites 
with very low concentrations may be dismissed when below the lasing threshold. As such, the 
development of higher-Q factor device is required in order to enhance the sensitivity and dynamic 
range for future laser-based detection.  
Last but not the least, we envision that this study will have significant impact in the 
following areas. (1) It will provide a new and powerful platform technology, which is 
complementary to conventional fluorescence based methods, for cell analysis and tissue analysis, 
both in vitro and in vivo. (2) The optofluidic laser based detection principle and protocol developed 
in this research are broadly applicable to any laser cavities  and any bio-species, and therefore, will 
lead to the development of novel on-chip devices for future clinical diagnosis, prognosis, and 
therapy. (3) Beyond biology and biomedicine, the study of the optofluidic tissue lasers will provide 
in-depth understanding of how light interacts with living organisms and biological materials, 
which will be significant for the development of novel bio-control photonic devices such as bio-
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